WO2023147306A2 - Biomarqueurs pour prédire la réactivité à une thérapie par inhibiteur de point de contrôle immunitaire - Google Patents
Biomarqueurs pour prédire la réactivité à une thérapie par inhibiteur de point de contrôle immunitaire Download PDFInfo
- Publication number
- WO2023147306A2 WO2023147306A2 PCT/US2023/061169 US2023061169W WO2023147306A2 WO 2023147306 A2 WO2023147306 A2 WO 2023147306A2 US 2023061169 W US2023061169 W US 2023061169W WO 2023147306 A2 WO2023147306 A2 WO 2023147306A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immune checkpoint
- checkpoint inhibitor
- tumor
- therapy
- genotype
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title claims abstract description 274
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title claims abstract description 274
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title claims abstract description 266
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title claims abstract description 266
- 239000000090 biomarker Substances 0.000 title claims abstract description 227
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 207
- 230000004043 responsiveness Effects 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 357
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 329
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 322
- 201000011510 cancer Diseases 0.000 claims abstract description 50
- 239000012472 biological sample Substances 0.000 claims abstract description 45
- 239000000523 sample Substances 0.000 claims description 208
- 230000003247 decreasing effect Effects 0.000 claims description 123
- 102000004034 Kelch-Like ECH-Associated Protein 1 Human genes 0.000 claims description 111
- 108090000484 Kelch-Like ECH-Associated Protein 1 Proteins 0.000 claims description 111
- 230000014509 gene expression Effects 0.000 claims description 111
- 108020004999 messenger RNA Proteins 0.000 claims description 104
- 102000004169 proteins and genes Human genes 0.000 claims description 99
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 claims description 97
- 102000002804 Ataxia Telangiectasia Mutated Proteins Human genes 0.000 claims description 96
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 86
- 230000035772 mutation Effects 0.000 claims description 81
- 230000005764 inhibitory process Effects 0.000 claims description 73
- 230000000415 inactivating effect Effects 0.000 claims description 61
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 60
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 60
- 102100038716 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 2 Human genes 0.000 claims description 57
- 102100027768 Histone-lysine N-methyltransferase 2D Human genes 0.000 claims description 57
- 101000883291 Homo sapiens Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 2 Proteins 0.000 claims description 57
- 101001008894 Homo sapiens Histone-lysine N-methyltransferase 2D Proteins 0.000 claims description 57
- 108010085793 Neurofibromin 1 Proteins 0.000 claims description 56
- 102000007530 Neurofibromin 1 Human genes 0.000 claims description 56
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 55
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims description 54
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims description 54
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 54
- 101000972918 Homo sapiens MAX gene-associated protein Proteins 0.000 claims description 50
- 101001052076 Homo sapiens Maltase-glucoamylase Proteins 0.000 claims description 50
- 102100022621 MAX gene-associated protein Human genes 0.000 claims description 50
- 238000002512 chemotherapy Methods 0.000 claims description 50
- 230000035945 sensitivity Effects 0.000 claims description 46
- 230000004044 response Effects 0.000 claims description 44
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 40
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 40
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 40
- -1 EP 300 Proteins 0.000 claims description 39
- 239000012634 fragment Substances 0.000 claims description 39
- 230000004614 tumor growth Effects 0.000 claims description 39
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 38
- 239000003112 inhibitor Substances 0.000 claims description 38
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 37
- 101150020330 ATRX gene Proteins 0.000 claims description 36
- 101150008921 Brca2 gene Proteins 0.000 claims description 36
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 claims description 36
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 claims description 36
- 208000020816 lung neoplasm Diseases 0.000 claims description 36
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 35
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 35
- 201000005202 lung cancer Diseases 0.000 claims description 34
- 108700020462 BRCA2 Proteins 0.000 claims description 33
- 102000052609 BRCA2 Human genes 0.000 claims description 33
- 102100035595 Cohesin subunit SA-2 Human genes 0.000 claims description 33
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 claims description 33
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims description 33
- 101001003194 Eleusine coracana Alpha-amylase/trypsin inhibitor Proteins 0.000 claims description 33
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims description 33
- 101000642968 Homo sapiens Cohesin subunit SA-2 Proteins 0.000 claims description 33
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 claims description 33
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims description 33
- 101000580092 Homo sapiens RNA-binding protein 10 Proteins 0.000 claims description 33
- 101000606537 Homo sapiens Receptor-type tyrosine-protein phosphatase delta Proteins 0.000 claims description 33
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims description 33
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims description 33
- 102100027514 RNA-binding protein 10 Human genes 0.000 claims description 33
- 102100039666 Receptor-type tyrosine-protein phosphatase delta Human genes 0.000 claims description 33
- 102100033254 Tumor suppressor ARF Human genes 0.000 claims description 33
- 108700042462 X-linked Nuclear Proteins 0.000 claims description 33
- 102000056014 X-linked Nuclear Human genes 0.000 claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 33
- 230000004565 tumor cell growth Effects 0.000 claims description 32
- 102100031561 Hamartin Human genes 0.000 claims description 31
- 101000795643 Homo sapiens Hamartin Proteins 0.000 claims description 31
- 102100023157 AT-rich interactive domain-containing protein 2 Human genes 0.000 claims description 30
- 101000685261 Homo sapiens AT-rich interactive domain-containing protein 2 Proteins 0.000 claims description 30
- 238000001514 detection method Methods 0.000 claims description 30
- 229960003301 nivolumab Drugs 0.000 claims description 30
- 229960002621 pembrolizumab Drugs 0.000 claims description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 30
- 229920001184 polypeptide Polymers 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 27
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 24
- 201000000849 skin cancer Diseases 0.000 claims description 24
- 238000012163 sequencing technique Methods 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 239000003153 chemical reaction reagent Substances 0.000 claims description 19
- 229940121420 cemiplimab Drugs 0.000 claims description 15
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 claims description 14
- 229960005386 ipilimumab Drugs 0.000 claims description 14
- 229940055760 yervoy Drugs 0.000 claims description 14
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 13
- 206010009944 Colon cancer Diseases 0.000 claims description 13
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 claims description 13
- 230000008859 change Effects 0.000 claims description 13
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 13
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 13
- 229950009791 durvalumab Drugs 0.000 claims description 12
- 229960001592 paclitaxel Drugs 0.000 claims description 12
- 229930012538 Paclitaxel Natural products 0.000 claims description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 11
- 229940123237 Taxane Drugs 0.000 claims description 11
- 239000003446 ligand Substances 0.000 claims description 11
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 11
- 201000002528 pancreatic cancer Diseases 0.000 claims description 11
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 11
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 11
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 10
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 10
- 229960003668 docetaxel Drugs 0.000 claims description 10
- 229960001573 cabazitaxel Drugs 0.000 claims description 9
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 8
- 238000011518 platinum-based chemotherapy Methods 0.000 claims description 8
- 229920002477 rna polymer Polymers 0.000 claims description 8
- 102100028908 Cullin-3 Human genes 0.000 claims description 6
- 102100037964 E3 ubiquitin-protein ligase RING2 Human genes 0.000 claims description 6
- 101000916238 Homo sapiens Cullin-3 Proteins 0.000 claims description 6
- 101001095815 Homo sapiens E3 ubiquitin-protein ligase RING2 Proteins 0.000 claims description 6
- 101001057193 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Proteins 0.000 claims description 6
- 101000728236 Homo sapiens Polycomb group protein ASXL1 Proteins 0.000 claims description 6
- 101000841471 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 15 Proteins 0.000 claims description 6
- 101000740048 Homo sapiens Ubiquitin carboxyl-terminal hydrolase BAP1 Proteins 0.000 claims description 6
- 101000740049 Latilactobacillus curvatus Bioactive peptide 1 Proteins 0.000 claims description 6
- 102100029799 Polycomb group protein ASXL1 Human genes 0.000 claims description 6
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 6
- 102100029164 Ubiquitin carboxyl-terminal hydrolase 15 Human genes 0.000 claims description 6
- 229960003852 atezolizumab Drugs 0.000 claims description 6
- 229950002916 avelumab Drugs 0.000 claims description 6
- 229940066453 tecentriq Drugs 0.000 claims description 6
- 108700020463 BRCA1 Proteins 0.000 claims description 5
- 102000036365 BRCA1 Human genes 0.000 claims description 5
- 101150072950 BRCA1 gene Proteins 0.000 claims description 5
- 102100021975 CREB-binding protein Human genes 0.000 claims description 5
- 102100031265 Chromodomain-helicase-DNA-binding protein 2 Human genes 0.000 claims description 5
- 108050006400 Cyclin Proteins 0.000 claims description 5
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 claims description 5
- 102100027085 Dual specificity protein phosphatase 4 Human genes 0.000 claims description 5
- 102100023387 Endoribonuclease Dicer Human genes 0.000 claims description 5
- 101710105178 F-box/WD repeat-containing protein 7 Proteins 0.000 claims description 5
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 claims description 5
- 108010067741 Fanconi Anemia Complementation Group N protein Proteins 0.000 claims description 5
- 102100027755 Histone-lysine N-methyltransferase 2C Human genes 0.000 claims description 5
- 101000896987 Homo sapiens CREB-binding protein Proteins 0.000 claims description 5
- 101000777079 Homo sapiens Chromodomain-helicase-DNA-binding protein 2 Proteins 0.000 claims description 5
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 claims description 5
- 101001053992 Homo sapiens Deleted in lung and esophageal cancer protein 1 Proteins 0.000 claims description 5
- 101000880945 Homo sapiens Down syndrome cell adhesion molecule Proteins 0.000 claims description 5
- 101001057621 Homo sapiens Dual specificity protein phosphatase 4 Proteins 0.000 claims description 5
- 101000966403 Homo sapiens Dynein light chain 1, cytoplasmic Proteins 0.000 claims description 5
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 claims description 5
- 101001008892 Homo sapiens Histone-lysine N-methyltransferase 2C Proteins 0.000 claims description 5
- 101001088887 Homo sapiens Lysine-specific demethylase 5C Proteins 0.000 claims description 5
- 101001025967 Homo sapiens Lysine-specific demethylase 6A Proteins 0.000 claims description 5
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 claims description 5
- 101000883014 Homo sapiens Protein capicua homolog Proteins 0.000 claims description 5
- 101000601770 Homo sapiens Protein polybromo-1 Proteins 0.000 claims description 5
- 101000824318 Homo sapiens Protocadherin Fat 1 Proteins 0.000 claims description 5
- 101001112424 Homo sapiens RB1-inducible coiled-coil protein 1 Proteins 0.000 claims description 5
- 101001130509 Homo sapiens Ras GTPase-activating protein 1 Proteins 0.000 claims description 5
- 101000591240 Homo sapiens Receptor-type tyrosine-protein phosphatase S Proteins 0.000 claims description 5
- 101001106322 Homo sapiens Rho GTPase-activating protein 7 Proteins 0.000 claims description 5
- 101000864057 Homo sapiens Serine/threonine-protein kinase SMG1 Proteins 0.000 claims description 5
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 claims description 5
- 101000795659 Homo sapiens Tuberin Proteins 0.000 claims description 5
- 101001087422 Homo sapiens Tyrosine-protein phosphatase non-receptor type 13 Proteins 0.000 claims description 5
- 101000744900 Homo sapiens Zinc finger homeobox protein 3 Proteins 0.000 claims description 5
- 102100033249 Lysine-specific demethylase 5C Human genes 0.000 claims description 5
- 102100037462 Lysine-specific demethylase 6A Human genes 0.000 claims description 5
- 229910015837 MSH2 Inorganic materials 0.000 claims description 5
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 claims description 5
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims description 5
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 5
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 claims description 5
- 102100038777 Protein capicua homolog Human genes 0.000 claims description 5
- 102100037516 Protein polybromo-1 Human genes 0.000 claims description 5
- 102100022095 Protocadherin Fat 1 Human genes 0.000 claims description 5
- 102100023588 RB1-inducible coiled-coil protein 1 Human genes 0.000 claims description 5
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 claims description 5
- 102100034102 Receptor-type tyrosine-protein phosphatase S Human genes 0.000 claims description 5
- 102100021446 Rho GTPase-activating protein 7 Human genes 0.000 claims description 5
- 102100034187 S-methyl-5'-thioadenosine phosphorylase Human genes 0.000 claims description 5
- 101710136206 S-methyl-5'-thioadenosine phosphorylase Proteins 0.000 claims description 5
- 102100029938 Serine/threonine-protein kinase SMG1 Human genes 0.000 claims description 5
- 102100031027 Transcription activator BRG1 Human genes 0.000 claims description 5
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims description 5
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 claims description 5
- 102100031638 Tuberin Human genes 0.000 claims description 5
- 102100033014 Tyrosine-protein phosphatase non-receptor type 13 Human genes 0.000 claims description 5
- 102100039966 Zinc finger homeobox protein 3 Human genes 0.000 claims description 5
- 101100002344 Caenorhabditis elegans arid-1 gene Proteins 0.000 claims description 4
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 claims description 4
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 claims description 4
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 claims description 4
- 102100030708 GTPase KRas Human genes 0.000 claims description 4
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 claims description 4
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 4
- 101000954986 Homo sapiens Merlin Proteins 0.000 claims description 4
- 101000830956 Homo sapiens Three-prime repair exonuclease 1 Proteins 0.000 claims description 4
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims description 4
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 4
- 102100037106 Merlin Human genes 0.000 claims description 4
- 102100024855 Three-prime repair exonuclease 1 Human genes 0.000 claims description 4
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims description 4
- 101001039256 Caenorhabditis elegans Low-density lipoprotein receptor-related protein Proteins 0.000 claims description 2
- 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 claims description 2
- 101001030069 Homo sapiens Major vault protein Proteins 0.000 claims description 2
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 claims description 2
- 101000738769 Homo sapiens Receptor-type tyrosine-protein phosphatase alpha Proteins 0.000 claims description 2
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 16
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims 9
- 102000016627 Fanconi Anemia Complementation Group N protein Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 62
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 58
- 150000007523 nucleic acids Chemical class 0.000 description 58
- 108020004414 DNA Proteins 0.000 description 57
- 102000039446 nucleic acids Human genes 0.000 description 56
- 108020004707 nucleic acids Proteins 0.000 description 56
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 42
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 37
- 210000001519 tissue Anatomy 0.000 description 32
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 31
- 239000002299 complementary DNA Substances 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 238000003752 polymerase chain reaction Methods 0.000 description 23
- 239000013598 vector Substances 0.000 description 23
- 238000002648 combination therapy Methods 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 19
- 238000003199 nucleic acid amplification method Methods 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 108091027544 Subgenomic mRNA Proteins 0.000 description 15
- 230000003321 amplification Effects 0.000 description 15
- 239000013615 primer Substances 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 108091034117 Oligonucleotide Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 230000008901 benefit Effects 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 102000040430 polynucleotide Human genes 0.000 description 12
- 108091033319 polynucleotide Proteins 0.000 description 12
- 238000010240 RT-PCR analysis Methods 0.000 description 11
- 239000002157 polynucleotide Substances 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 9
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 239000002987 primer (paints) Substances 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000007481 next generation sequencing Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 108091023037 Aptamer Proteins 0.000 description 7
- 230000004075 alteration Effects 0.000 description 7
- 238000001574 biopsy Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 102000008096 B7-H1 Antigen Human genes 0.000 description 6
- 108010074708 B7-H1 Antigen Proteins 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 6
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 150000003384 small molecules Chemical group 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 238000013528 artificial neural network Methods 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000004055 small Interfering RNA Substances 0.000 description 5
- 108091033409 CRISPR Proteins 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 102100040884 Partner and localizer of BRCA2 Human genes 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- 238000003559 RNA-seq method Methods 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000004077 genetic alteration Effects 0.000 description 4
- 208000025750 heavy chain disease Diseases 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 238000007482 whole exome sequencing Methods 0.000 description 4
- 238000012070 whole genome sequencing analysis Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 101150041972 CDKN2A gene Proteins 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 101100492811 Drosophila melanogaster tefu gene Proteins 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 3
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 description 3
- 101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 description 3
- 101000984620 Homo sapiens Low-density lipoprotein receptor-related protein 1B Proteins 0.000 description 3
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 3
- 101000974349 Homo sapiens Nuclear receptor coactivator 6 Proteins 0.000 description 3
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 102100027121 Low-density lipoprotein receptor-related protein 1B Human genes 0.000 description 3
- 101100354354 Mus musculus Ptprd gene Proteins 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 102100022929 Nuclear receptor coactivator 6 Human genes 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 231100000118 genetic alteration Toxicity 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000010208 microarray analysis Methods 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 230000007730 Akt signaling Effects 0.000 description 2
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 229920002274 Nalgene Polymers 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108020005067 RNA Splice Sites Proteins 0.000 description 2
- 108091008103 RNA aptamers Proteins 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 101710204410 Scaffold protein Proteins 0.000 description 2
- 238000012896 Statistical algorithm Methods 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 190000008236 carboplatin Chemical compound 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000008004 cell lysis buffer Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012520 frozen sample Substances 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000010841 mRNA extraction Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 238000007637 random forest analysis Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 102200006539 rs121913529 Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000003196 serial analysis of gene expression Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229940121497 sintilimab Drugs 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229950007213 spartalizumab Drugs 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000007671 third-generation sequencing Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102100034580 AT-rich interactive domain-containing protein 1A Human genes 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000012791 Alpha-heavy chain disease Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 101100310856 Drosophila melanogaster spri gene Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 101000633756 Echis pyramidum leakeyi Snaclec 4 Proteins 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 101150095705 FBXW7 gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000924266 Homo sapiens AT-rich interactive domain-containing protein 1A Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 208000007866 Immunoproliferative Small Intestinal Disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 238000012897 Levenberg–Marquardt algorithm Methods 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 101150033433 Msh2 gene Proteins 0.000 description 1
- 208000012799 Mu-heavy chain disease Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 229940028652 abraxane Drugs 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 208000025751 alpha chain disease Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000000220 brain stem cancer Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000005200 bronchus cancer Diseases 0.000 description 1
- 229950007712 camrelizumab Drugs 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940121432 dostarlimab Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 201000010255 female reproductive organ cancer Diseases 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011773 genetically engineered mouse model Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 229950008991 lobaplatin Drugs 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000026114 mu chain disease Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
- 210000004296 naive t lymphocyte Anatomy 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- NYDXNILOWQXUOF-GXKRWWSZSA-L pemetrexed disodium Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-GXKRWWSZSA-L 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 208000029255 peripheral nervous system cancer Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 238000011451 sequencing strategy Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000012409 standard PCR amplification Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 238000001847 surface plasmon resonance imaging Methods 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013066 thyroid gland cancer Diseases 0.000 description 1
- 229950007123 tislelizumab Drugs 0.000 description 1
- 229940121514 toripalimab Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
Definitions
- compositions and methods comprising biomarker genes for identifying subjects that are likely to respond to immune checkpoint inhibitor therapies.
- Non-small-cell lung cancer which is the most common type, accounts for 80% to 85% of all lung cancer diagnoses. It is frequently diagnosed in the advanced stage, with 5-year survival rates ranging from 0% to 5% with chemotherapy, the only systemic therapeutic strategy available for decades.
- blockade of the programmed cell death-1 (PD-l)/programmed death ligand-1 (PD-L1) axis has opened new avenues in the lung cancer therapeutic landscape, increasing overall survival (OS) not only in patients with advanced NSCLC but also in patients with stage III NSCLC and extensive-stage small-cell lung cancer.
- OS overall survival
- CTLA-4 cytotoxic T-lymphocyte-associated protein-4
- PD-1 cytotoxic T-lymphocyte-associated protein-4
- TCR T-cell receptor
- Both proteins are induced on T cells upon T-cell receptor (TCR) signaling activation, albeit with different kinetics.
- CTLA-4 is generally up-regulated during the initial stage of naive T-cell activation and competes with CD28 for the same ligands (CD86 and CD80) expressed on antigen presenting cells (APCs).
- APCs antigen presenting cells
- CTLA-4 is constitutively expressed at high levels on regulatory T cells and constitutes one of the regulatory T cells’ immunosuppressive mechanisms.
- PD-1 is generally induced during the later phases of an immune response, controlling previously activated T cells, typically at the effector sites of immune responses.
- CTLA-4 and PD-1 immune checkpoints are particularly deregulated in tumorbearing hosts, where chronic ineffective immune responses routinely predominate and result in T-cell exhaustion and induction of regulatory T cells.
- Inhibition of PD-1 has achieved clinical success in chemotherapy-refractory advanced non-small cell lung cancer (NSCLC) patients, where it is currently being investigated in combination with CTLA-4 inhibition. Inhibition of PD-1 as a monotherapy or in combination with CTLA-4 inhibition can produce notable clinical benefits. However, there are no validated biomarkers guiding selection of subjects that are likely to benefit from checkpoint inhibitor therapy or for those subjects who are not likely to respond. The present disclosure addresses this need and provides related advantages.
- compositions and methods are provided for identifying subjects that will respond to immune checkpoint inhibitor therapies.
- the present disclosure provides a method comprising: (a) determining a genotype of one or more biomarker genes of a biomarker panel comprising APC, ARID 1 A, ARID2, ASXL1, ATM, ATRX, BAP1, BRCA1, BRCA2, CDKN2A, CHD2, CIC, CMTR2, CREBBP, CUL3, DICER1, DLC1, DUSP4, EP300, FAT1, FBXW7, KDM5C, KDM6A, KEAP1, KMT2C, KMT2D, KRASWT, LKB1, LRP1B, MG A, MSH2, MTAP, NCOA6, NF1, NF 2, P53, PALB2, PBRM1, PCNA, PTEN, PTPN13, PTPRD, PTPRS, RASA1, RBI, RB1CC1, RBM10, RNF43, SETD2, SHP2, SMAD2, SMAD4, SMARCA4, SMG1, STAG2, TET2, TGFBR
- the biomarker panel comprises APC, ARID2, ATM, ATRX, BRCA2, CDKN2A, CMTR2, KEAP1, KMT2D, MGA, NF1, PTEN, PTPRD, RBI, RBM10, RNF43, SETD2, SMAD4, STAG2, STK11, TP53, and TSC1.
- the biomarker panel comprises APC, ARID2, ATM, ATRX, CMTR2, KEAP1, KMT2D, MGA, NF1, PTEN, PTPRD, RBI, RBM10, RNF43, SETD2, SMAD4, STAG2, SIKH, and TSC1.
- the biomarker panel comprises BRCA2, CDKN2A, and TP53. In certain embodiments, the biomarker panel comprises APC, CMTR2, KEAP1, KMT2D, MGA, and NF J. In certain embodiments, the biomarker panel comprises ATM.
- the genotype comprises a mutation in the one or more biomarker genes.
- the mutation inactivates the one or more biomarker genes.
- the method further comprises comparing the genotype with a reference genotype.
- the reference is to an untreated population.
- the reference is to a treated population.
- the genotype is reported as a score.
- determining the genotype comprises genomic profiling. In certain embodiments, determining the genotype comprises measuring gene expression. In certain embodiments, measuring gene expression comprises detection of ribonucleic acids (RNAs) or polypeptides.
- RNAs ribonucleic acids
- the subject is classified as sensitive to an immune checkpoint inhibitor treatment. In certain embodiments, the subject is classified as resistant to an immune checkpoint inhibitor treatment.
- the immune checkpoint inhibitor comprises an antibody or an antigen-binding fragment thereof. In certain embodiments, the immune checkpoint inhibitor inhibits programmed cell death protein 1 (PD-1). In certain embodiments, the immune checkpoint inhibitor is an anti -PD-1 antibody. In certain embodiments, the immune checkpoint inhibitor is selected from the group consisting of Nivolumab (Opdivo), Pembrolizumab (Keytruda), and Cemiplimab (Libtayo).
- the immune checkpoint inhibitor inhibits cytotoxic T- lymphocyte-associated antigen 4 (CTLA-4).
- CTLA-4 cytotoxic T- lymphocyte-associated antigen 4
- the immune checkpoint inhibitor is an anti-CTLA-4 antibody.
- the immune checkpoint inhibitor is Ipilimumab (Yervoy).
- the immune checkpoint inhibitor inhibits programmed cell death protein 1 ligand (PD-L1).
- the immune checkpoint inhibitor is an anti-PD-Ll antibody.
- the immune checkpoint inhibitor is selected from the group consisting of Atezolizumab (Tecentriq), Avelumab (Bevencio), and Durvalumab (Imfinzi).
- the methods of the present dislcousre further comprise administering an immune checkpoint inhibitor therapy to the subject.
- the methods comprise administering to the subject a combination therapy comprising two distinct checkpoint inhibitors.
- the methods comprise administering to the subject a combination therapy comprising a checkpoint inhibitor and a second therapy.
- the second therapy is chemotherapy.
- the chemotherapy comprises first-line platinum chemotherapy.
- the chemotherapy comprises taxane-based chemotherapy.
- the taxane is selected from the group consisting of docetaxel, paclitaxel, and cabazitaxel.
- the taxane is docetaxel.
- the present disclosure provides a method of predicting resistance of tumor growth to inhibition by a therapy comprising an immune checkpoint inhibitor, comprising: (a) detecting in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting resistance of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating BRCA2, CDKN2A, or TP53 mutation, (ii) a decreased copy number of BRCA2, CDKN2A, or TP53, or (iii) a decreased expression of BRCA2, CDKN2A, or TP53 mRNA or protein.
- the present disclosure provides a method of predicting resistance of tumor growth to inhibition by a therapy comprising an immune checkpoint inhibitor, comprising: (a) detecting in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting resistance of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating ATM mutation, (ii) a decreased copy number of ATM, or (iii) a decreased expression of ATM mRNA or protein.
- the present disclosure provides a method of predicting resistance of tumor growth to inhibition by a therapy comprising an immune checkpoint inhibitor, comprising: (a) detecting in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting resistance of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating TP53 mutation, (ii) a decreased copy number of TP53, or (iii) a decreased expression of TP53 mRNA or protein.
- the present disclosure provides a method of predicting sensitivity of tumor growth to inhibition by a therapy comprising an immune checkpoint inhibitor, comprising: (a) detecting in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting sensitivity of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating APC, ARID2, ATM, ATRX, CMTR2, KEAP1, KMT2D, MGA, NF1, PTEN, PTPRD, RBI, RBM10, RNF43, SETD2, SMAD4, STAG2, STK11, or TSC1 mutation, (ii) a decreased copy number of APC, ARID2, ATM, ATRX, CMTR2, KEAP1, KMT2D, MGA, NF1, PTEN, PTPRD, RBI, RBM10, RNF43, SETD
- the present disclosure provides a method of predicting sensitivity of tumor growth to inhibition by a therapy comprising an immune checkpoint inhibitor, comprising: (a) detecting in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting sensitivity of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating APC, CMTR2, KEAP1, KMT2D, MGA, or NF1 mutation, (ii) a decreased copy number of APC, CMTR2, KEAP1, KMT2D, MGA, or NF1, or (iii) decreased expression of APC, CMTR2, KEAP1, KMT2D, MGA, or NF1 mRNA or protein.
- the present disclosure provides a method of predicting sensitivity of tumor growth to inhibition by a therapy comprising an immune checkpoint inhibitor, comprising: (a) detecting in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting sensitivity of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating APC mutation, (ii) a decreased copy number of APC, or (iii) decreased expression of APC mRNA or protein.
- the present disclosure provides a method of predicting response of tumor growth to inhibition by a therapy comprising an immune checkpoint inhibitor, comprising: (a) determining in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting the response of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating APC, ARID2, ATM, ATRX, CMTR2, KEAP1, KMT2D, MGA, NF1, PTEN, PTPRD, RBI, RBM10, RNF43, SETD2, SMAD4, STAG2, STK11, or TSC1 mutation, (ii) a decreased copy number of APC, ARID2, ATM, ATRX, CMTR2, KEAP1, KMT2D, MGA, NF1, PTEN, PTPRD, RBI, RBM10, RNF43, SETD2,
- the present disclosure provides a method of predicting response of tumor growth to inhibition by a therapy comprising an immune checkpoint inhibitor, comprising: (a) determining in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting the response of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating APC, CMTR2, KEAP1, KMT2D, MGA, or NF1 mutation, (ii) a decreased copy number of APC, CMTR2, KEAP1, KMT2D, MGA, or NF1, (iii) decreased expression of APC, CMTR2, KEAP1, KMT2D, MGA, or NF1 mRNA or protein; (iv) an inactivating ATM mutation, (v) a decreased copy number of ATM, or (vi) a decreased expression of ATM m
- the present disclosure provides a method of treating non-small cell lung cancer (NSCLC) comprising the step of treating a subject with a immune checkpoint inhibitor when a tumor sample obtained from the subject comprises (i) an inactivating APC, CMTR2, KEAP1, KMT2D, MGA, or NF1 mutation, (ii) a decreased copy number of APC, CMTR2, KEAP1, KMT2D, MGA, or NF1, or (iii) decreased expression of APC, CMTR2, KEAP1, KMT2D, MGA, or NF1 mRNA or protein.
- NSCLC non-small cell lung cancer
- the tumor sample obtained from the subject further comprises (iv) absence of an inactivating ATM mutation, (v) absence of a decreased copy number cT A TM, or (vi) absence of decreased expression cT A TM mRNA or protein.
- the present disclosure provides a method of predicting resistance of tumor growth to inhibition by an immune checkpoint inhibitor therapy comprising a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, the method comprising: (a) detecting in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting resistance of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating ATM mutation, (ii) a decreased copy number of ATM, or (iii) a decreased expression of ATM mRNA or protein.
- CTLA-4 cytotoxic T-lymphocyte-associated antigen 4
- the present disclosure provides a method of predicting sensitivity of tumor growth to inhibition by an immune checkpoint inhibitor therapy comprising a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, the method comprising: (a) detecting in a tumor sample of a subject a genotype of one or more biomarker genes of a biomarker panel comprising; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting sensitivity of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating KEAP1 mutation, (ii) a decreased copy number of KEAP1, or (iii) decreased expression of KEAP1 mRNA or protein.
- CTLA-4 cytotoxic T-lymphocyte-associated antigen 4
- the present disclosure provides a method of predicting response of tumor growth to inhibition by an immune checkpoint inhibitor therapy comprising a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, the method comprising: (a) determining in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting the response of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating KEAP1 mutation, (ii) a decreased copy number of KEAP1, (iii) decreased expression of KEAP1 mRNA or protein, (iv) an inactivating ATM mutation, (v) a decreased copy number of ATM, or (vi) a decreased expression of ATM mRNA or protein.
- CTLA-4 cytotoxic T-lymphocyte-associated antigen 4
- the present disclosure provides a method of enriching a prospective patient population for subjects likely to respond to an immune checkpoint inhibitor therapy, for example, a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor therapy, the method comprising performing the methods described herein of predicting sensitivity, resistance and/or response of tumor growth to inhibition by an immune checkpoint inhibitor therapy on two or more individual subjects within the prospective patient population.
- an immune checkpoint inhibitor therapy for example, a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor therapy
- the present disclosure provides a method of treating non-small cell lung cancer (NSCLC), comprising treating a subject with an immune checkpoint inhibitor when a tumor sample obtained from the subject comprises (i) an inactivating KEAP1 mutation, (ii) a decreased copy number of KEAP1, or (iii) decreased expression of KEAP1 mRNA or protein.
- NSCLC non-small cell lung cancer
- the present disclosure provides a method of treating non-small cell lung cancer (NSCLC), comprising treating a subject with a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor when a tumor sample obtained from the subject comprises (i) an inactivating KEAP1 mutation, (ii) a decreased copy number of KEAP1, or (iii) decreased expression of KEAP1 mRNA or protein.
- NSCLC non-small cell lung cancer
- the subject is already undergoing an immune checkpoint inhibitor therapy comprising a programmed cell death protein 1 (PD-1) inhibitor and a chemotherapy.
- PD-1 inhibitor is selected from the group consisting of nivolumab (Opdivo), Pembrolizumab (Keytruda), and Cemiplimab (Libtayo).
- the chemotherapy comprises a taxane, for example, docetaxel, paclitaxel or cabazitaxel.
- the methods further comprise selecting a therapy for the subject.
- the therapy comprises a CTLA-4 inhibitor, for example, Ipilimumab (Yervoy).
- the present disclosure provides a method of treating non-small cell lung cancer (NSCLC), comprising treating a subject undergoing a therapy comprising a first immune checkpoint inhibitor and a chemotherapy with a second immune checkpoint inhibitor when a tumor sample obtained from the subject comprises (i) an inactivating KEAP1 mutation, (ii) a decreased copy number of KEAP1, or (iii) decreased expression of KEAP1 mRNA or protein.
- NSCLC non-small cell lung cancer
- the first immune checkpoint inhibitor inhibits programmed cell death protein 1 (PD-1), for example, an anti -PD-1 antibody, e.g., nivolumab (Opdivo), Pembrolizumab (Keytruda), and Cemiplimab (Libtayo).
- PD-1 programmed cell death protein 1
- the second immune checkpoint inhibitor comprises an cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, for example, an anti-CTLA-4 antibody.
- CTLA-4 cytotoxic T-lymphocyte-associated antigen 4
- the present disclosure provides a method of determining effectiveness of an immune checkpoint inhibitor in reducing tumor size comprising: (a) treating a first inert tumor with a control therapy; (b) treating a second inert tumor with an immune checkpoint inhibitor, wherein the first and second inert tumors comprise identical genotypes; (c) treating a first mutant tumor with the control therapy; (d) treating a second mutant tumor with the immune checkpoint inhibitor, wherein the first and second mutant tumors comprise identical genotypes; (e) comparing sizes of the first and second inert tumors after the therapy; (f) comparing sizes of the first and second mutant tumors after completion of the therapy, and (g) identifying the mutant tumor genotype as sensitive to the immune checkpoint inhibitor if the change in tumor size between the first and second inert tumors after the therapy is less than the change in tumor size between the first and second mutant tumors after the therapy.
- the present disclosure provides a method of determining effectiveness of an immune checkpoint inhibitor in reducing tumor size comprising: (a) treating a first inert tumor with a control therapy; (b) treating a second inert tumor with an immune checkpoint inhibitor, wherein the first and second inert tumors comprise identical genotypes; (c) treating a first mutant tumor with the control therapy; (d) treating a second mutant tumor with the immune checkpoint inhibitor, wherein the first and second mutant tumors comprise identical genotypes; (e) comparing sizes of the first and second inert tumors after the therapy; (f) comparing sizes of the first and second mutant tumors after completion of the therapy, and (g) identifying the mutant tumor genotype as resistant to the immune checkpoint inhibitor if the change in tumor size between the first and second inert tumors after the therapy is greater than the change in tumor size between the first and second mutant tumors after the therapy.
- the cancer is a skin cancer, lung cancer, pancreatic cancer, breast cancer, or colorectal cancer.
- the cancer is lung cancer.
- the lung cancer is non-small cell lung cancer (NSCLC).
- the NSCLC is lung adenocarcinoma.
- FIG. 1 shows bootstrap confidence intervals for RTNscore for each of the twenty-two biomarker genes tested as described in Example 1.
- the left column shows RTNscore values when a minimal size cutoff of 500 cell was applied to the treated tumors, while the right columns show RTNscore when a large cutoff of 5000 cells was used.
- Each row gives the results of a different treatment study arm.
- Confidence intervals are displayed in the form of Letter-value plots: the central box shows the median and interquartile range of the bootstrap distribution, and every subsequent box edge shows the location of the 50 th percentile of bootstraps beyond the previous box edge.
- FIG. 2E shows multiplexed analysis of immunotherapy responses in an autothchonous mouse model of lung adenocarcinoma as described in FIG. 1.
- FIG. 2A shows an experimental schematic depicting the composition of the pool of barcoded Lenti-sgRNA/Cre vectors (Lenti-D2G ⁇ ‘P° 0 Cre) used in Example 1.
- FIG. 2B shows mouse genotype, analysis time points, and readouts.
- FIG. 2C shows effects of each tumor genotype on growth. Tumors at the indicated percentiles of the tumor size distribution for each barcoded Lenti-sgRNA/Cre vector are shown. 95% confidence intervals are indicated.
- FIG. 2D shows the treatment groups in this study.
- FIG. 2E shows overall responses to therapies, each dot represents a mouse. Antibodies, dosing, and number of mice are indicated.
- FIG. 3A - FIG. 3D shows that Keapl -deficiency drives selective sensitivity to combination PD-1 inhibitor- and CTLA-4 inhibitor therapy in vivo.
- FIG. 3A and FIG. 3B show genotype specific responses to PD-1 inhibitor-treated relative to control -treated mice (FIG. 3A) and PD-1 inhibitor- and CTLA-4 inhibitor-treated mice relative to control treated mice (FIG. 3B).
- Significant sensitive effects are shown for Ape in FIG. 3 A, and Ape, Cmtr2, Keapl, Kmt2d, and Nfl in FIG. 3B.
- Significant resistant effects are shown for Atm in FIG. 3B.
- FIG. 3C shows genotype specific responses to PD-1 inhibitor-treated and CTLA-4 inhibitor-treated mice relative to PD-1 inhibitor-treated mice. Significant sensitive effects are shown for Keapl and significant resistant effects are shown for Atm in FIG. 3C.
- FIG. 3D shows a volcano plot of the magnitude of differential sensitivity to a PD-1 inhibitor treatment and a CTLA-4 inhibitor treatment relative to a PD-1 inhibitor treatment alone.
- the present disclosure is based, at least in part, on the surprising discovery that the genotype of particular biomarker genes can be used to predict a subject’s response to an immune checkpoint inhibitor therapy.
- the genotype is predictive of sensitivity to a checkpoint inhibitor therapy.
- the genotype is predictive of resistance to a checkpoint inhibitor therapy.
- the present disclosure provides new and advantageous methods for determining whether a subject afflicted with a tumor (e.g., cancer) is a candidate for an immune checkpoint inhibitor therapy.
- the present disclosure is further based, in part, on the surprising discovery that KEAP /-deficiency drives selective sensitivity to a combination therapy comprising a PD-1 inhibitor and a CTLA-4 inhibitor, while A 7A/-deficiency drives selective resistance to a combination therapy comprising a PD-1 inhibitor and a CTLA-4 inhibitor.
- This discovery disclosed herein has important implications for the identification of subjects undergoing a PD-1 inhibitor therapy, for example, in combination with chemotherapy, who can benefit from the addition of a CTLA-4 inhibitor therapy to their treatment regimen.
- the present disclosure provides a method comprising: (a) determining the genotype of one or more biomarker genes in a biological sample of a subject; (b) identifying whether the subject is likely to be sensitive to a therapy comprising an immune checkpoint inhibitor based on the genotype.
- the present disclosure provides a method comprising: (a) determining the genotype of one or more biomarker genes in a biological sample of a subject; (b) identifying whether the subject is likely to be sensitive to a therapy comprising an immune checkpoint inhibitor based on the genotype.
- the methods further comprise administering to the subject the immune checkpoint inhibitor if the subject is identified as likely to be sensitive to a therapy comprising an immune checkpoint inhibitor.
- the biomarker genes useful in the methods of the present disclosure are ADAR, APC, ARID1A, ARID2, ASXL1, ATM, ATRX, BAP1, BRCA1, BRCA2, CDKN2A, CHD2, CIC, CMTR2, CREBBP, CUL3, DICER1, DLC1, DNMT1, DUSP4, EP300, FAT1, FBXW7, JAK1, KDM5C, KDM6A, KEAP1, KMT2C, KMT2D, KRAS, LRP1B, MET, MGA, MSH2, MTAP, NCOA6, NF1, NF2, PALB2, PBRM1, PCNA, PTEN, PTPN11, PTPN13, PTPRD, PTPRS, RASA1, RBI, RB1CC1, RBM10, RNF43, SETD2, SMAD2, SMAD4, SMARCA4, SMG1, STAG2, SIKH, TET2, TGFBR2, TREX1, TP53, T
- the biomarker genes useful in the methods of the present disclosure are ZPC, ARID2, ATM, ATRX, BRCA2, CDKN2A, CMTR2, KEAP1, KMT2D, MGA, NF1, PTEN, PTPRD, RBI, RBM10, RNF43, SETD2, SMAD4, STAG2, STK11, TP53, and TSC1.
- the biomarker genes useful in the methods of the present disclosure are APC, ARID2, ATM, ATRX, CMTR2, KEAP1, KMT2D, MGA, NF1, PTEN, PTPRD, RBI, RBM10, RNF43, SETD2, SMAD4, STAG2, SIKH, and TSC1.
- biomarker genes useful in the methods of the present disclosure are BRCA2, CDKN2A, and TP53.
- the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having,” “contains” or “containing,” or any other variation thereof, will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers and are intended to be non-exclusive or open-ended.
- a composition, a mixture, a process, a method, an article, or an apparatus that comprises a list of elements is not necessarily limited to only those elements but can include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus.
- “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
- the conjunctive term “and/or” between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by “and/or,” a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and therefore satisfy the requirement of the term “and/or” as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and therefore satisfy the requirement of the term “and/or.”
- the term “subject” refers to any organism, e.g., a mammal, for whom diagnosis, prognosis, or therapy is desired.
- Mammalian subjects include, but are not limited to, humans, domestic animals, farm animals, sports animals, and zoo animals including, for example, humans, non-human primates, dogs, cats, guinea pigs, rabbits, rats, mice, horses, and cattle.
- the subject has been diagnosed with cancer.
- the subject is a human afflicted with a tumor (e.g., cancer) who has been diagnosed with a need for treatment for a tumor (e.g., cancer).
- inhibitor is an active agent that inhibits, blocks, or suppresses biological activity in vitro or in vivo.
- Inhibitors include but are not limited to small molecule compounds; nucleic acids, such as siRNA and shRNA; polypeptides, such as antibodies or antigen-binding fragments thereof, dominant-negative polypeptides, and inhibitory peptides; and oligonucleotide or peptide aptamers.
- Immune checkpoint inhibitor is any active agent that antagonizes the activity of an immune checkpoint protein or its ligand or reduces its production in a cell.
- Immune checkpoint proteins include, but are not limited to, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), also known as CD152, programmed cell death protein 1 (PD-1), also known as CD279, lymphocyte-activation gene 3 (LAG-3), also known as CD223, and T cell immunoglobulin mucin (TIM-3), also known as HAVcr2.
- CTLA-4 inhibitor is an active agent that antagonizes the activity of cytotoxic T lymphocyte-associated antigen 4 or reduces its production in a cell.
- PD-1 inhibitor is an active agent that antagonizes the activity of programmed cell death protein 1 or reduces its production in a cell.
- PD-1 inhibitors also include active agents that inhibit the PD-1 ligand (PD-L1).
- the immune checkpoint inhibitor of PD-1 is an anti-PD-1 antibody.
- Non-limiting exemplary immune checkpoint inhibitors of programmed cell death protein 1 (PD-1) include nivolumab (Opdivo), Pembrolizumab (Keytruda), and Cemiplimab (Libtayo).
- the immune checkpoint inhibitor of CTLA-4 is an anti- CTLA-4 antibody.
- Non-limiting exemplary immune checkpoint inhibitors of CTLA-4 include Ipilimumab (Yervoy).
- the immune checkpoint inhibitor of PD-L1 is an anti-PD-Ll antibody.
- Non-limiting exemplary immune checkpoint inhibitors of PD-L1 include Atezolizumab (Tecentriq), avelumab (Bevencio), durvalumab (Imfinzi).
- exemplary immune checkpoint inhibitors presently under development and/or undergoing clinical trials include JTX-4014 (Jounce Therapeutics), Spartalizumab (PDR001) a PD-1 inhibitor developed by Novartis; Camrelizumab (SHR1210) an anti-PD-1 monoclonal antibody by Jiangsu HengRui Medicine Co., Ltd.
- Sintilimab (IBI308), a human anti-PD-1 antibody developed by Innovent and Eli Lilly; Tislelizumab (BGB-A317) a humanized IgG4 anti-PD-1 monoclonal antibody; Toripalimab (JS 001) a humanized IgG4 monoclonal antibody against PD-1; Dostarlimab (TSR-042, WBP-285) a humanized monoclonal antibody against PD-1 by GlaxoSmithKline; INCMGA00012 (MGA012) a humanized IgG4 monoclonal antibody developed by Incyte and MacroGenics; AMP -224 by AstraZeneca/Medlmmune and GlaxoSmithKline; and AMP-514 (MEDI0680) by AstraZeneca; Tremelimumab, as CTL-4 inhibitor and PD-L1 inhibitors KN035 and CK-301 Checkpoint Therapeutics; as well as AU
- the immune checkpoint inhibitor is a small molecule. In certain embodiments, the immune checkpoint inhibitor is a polypeptide. In certain embodiments, the immune checkpoint inhibitor is a polypeptide analog. In certain embodiments, the immune checkpoint inhibitor is a peptidomimetic. In certain embodiments, the immune checkpoint inhibitor is an aptamer.
- an immune checkpoint inhibitor is an antibody or an antigenbinding fragment thereof.
- the antibody or antigen-binding fragment thereof can be a humanized antibody, a recombinant antibody, a diabody, a chimerized or chimeric antibody, a monoclonal antibody, a deimmunized antibody, a fully human antibody, a single chain antibody, an F v fragment, an Fa fragment, a Fab fragment, an Fab' fragment, or an F(ab')2 fragment.
- an inhibitor of an immune checkpoint protein can be, for example, a small molecule, a nucleic acid or nucleic acid analog, a peptidomimetic, or a macromolecule that is not a nucleic acid or a protein.
- agents include, but are not limited to, small organic molecules, RNA aptamers, L-RNA aptamers, Spiegelmers, antisense compounds, double stranded RNA, small interfering RNA, locked nucleic acid inhibitors, and peptide nucleic acid inhibitors.
- an immune checkpoint inhibitor is a protein or a protein fragment.
- RNA interference such as double stranded RNA including small interfering RNA (siRNA), locked nucleic acid (LNA) inhibitors, peptide nucleic acid (PNA) inhibitors, etc.
- the immune checkpoint protein inhibitor is an antibody or an antigen-binding fragment thereof, which binds to an immune checkpoint protein.
- antibody is used in a broad sense and includes immunoglobulin or antibody molecules including human, humanized, composite and chimeric, single-chain, bi-specific and multi-specific antibodies and antibody fragments, in particular, antigen-binding fragments, that are monoclonal or polyclonal.
- antibodies are proteins or peptide chains that exhibit binding specificity to a specific antigen.
- Antibody structures are well known. Immunoglobulins can be assigned to five major classes (specifically, IgA, IgD, IgE, IgG and IgM), depending on the heavy chain constant domain amino acid sequence.
- IgA and IgG are further sub-classified as the isotypes IgAl, IgA2, IgGl, IgG2, IgG3 and IgG4. Accordingly, the antibodies provided herein can be of any of the five major classes or corresponding sub-classes. In certain embodiments, the antibodies provided herein are IgGl, IgG2, IgG3 or IgG4. Antibody light chains of vertebrate species can be assigned to one of two clearly distinct types, namely kappa and lambda, based on the amino acid sequences of their constant domains.
- An immune checkpoint inhibitor of can also be, for example, a small molecule, a polypeptide analog, a nucleic acid, or a nucleic acid analog.
- Small molecule as used herein, is meant to refer to an agent, which has a molecular weight preferably of less than about 6 kDa and most preferably less than about 2.5 kDa.
- Many pharmaceutical companies have extensive libraries of chemical and/or biological mixtures comprising arrays of small molecules, often fungal, bacterial, or algal extracts, which can be screened with any of the assays of the application. It is within the scope of this application that such a library can be used to screen for agents that bind to a target antigen of interest (for example, an immune checkpoint protein).
- the immune checkpoint inhibitor is a nucleic acid inhibitor.
- Nucleic acid inhibitors can be used to bind to and inhibit a target antigen of interest.
- the nucleic acid antagonist can be, for example, an aptamer.
- Aptamers are short oligonucleotide sequences that can be used to recognize and specifically bind almost any molecule, including cell surface proteins. The systematic evolution of ligands by exponential enrichment (SELEX) process is powerful and can be used to readily identify such aptamers. Aptamers can be made for a wide range of proteins of importance for therapy and diagnostics, such as growth factors and cell surface antigens. These oligonucleotides bind their targets affinities and specificities similar to those of antibodies.
- the immune checkpoint inhibitor is a non-antibody scaffold protein.
- These proteins are, generally, obtained through combinatorial chemistry-based adaptation of pre-existing antigen-binding proteins.
- the binding site of human transferrin for human transferrin receptor can be modified using combinatorial chemistry to create a diverse library of transferrin variants, some of which have acquired affinity for different antigens.
- the portion of human transferrin not involved with binding the receptor remains unchanged and serves as a scaffold, like framework regions of antibodies, to present the variant binding sites.
- the libraries are then screened, as an antibody library is, against a target antigen of interest to identify those variants having optimal selectivity and affinity for the target antigen.
- Non-antibody scaffold proteins while similar in function to antibodies, are claimed as having a number of advantages as compared to antibodies, which advantages include, among other things, enhanced solubility and tissue penetration, less costly manufacture, and ease of conjugation to other molecules of interest.
- advantages include, among other things, enhanced solubility and tissue penetration, less costly manufacture, and ease of conjugation to other molecules of interest.
- “inhibited” means terminated, reduced, delayed or prevented.
- Tumor growth is also “inhibited” if recurrence or metastasis of the cancer is reduced, slowed, delayed or prevented.
- reducing the tumor means reducing the size, volume, or weight of the tumor, reducing the number of metastases, reducing the size or weight of a metastasis, or combinations thereof.
- a metastasis is cutaneous or subcutaneous.
- administration of the immune checkpoint inhibitor reduces the size or volume of the tumor by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, at least about 95%, at least about 98% or at least about 99%, for example, relative to a control drug in a subject of the same genotype.
- administration of the immune checkpoint inhibitor reduces the weight of the tumor by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, at least about 95%, at least about 98% or at least about 99%, for example, relative to a control drug in a subject of the same genotype.
- administration of the immune checkpoint inhibitor reduces the size or volume of a metastasis by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, at least about 95%, at least about 98% or at least about 99%, for example, relative to a control drug in a subject of the same genotype.
- administration of the immune checkpoint inhibitor reduces the number of metastases by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, at least about 95%, at least about 98% or at least about 99% for example, relative to a control drug in a subject of the same genotype. In certain embodiments, combinations of these effects are achieved.
- a “biomarker gene” can be any gene having a genotype and/or expression level that can be determined, measured and/or evaluated as an indicator of a biologic process, pathogenic process, or pharmacologic response to a therapeutic intervention.
- a biomarker gene useful to practice the presently disclosed methods can be used as an indicator to determine whether a subject having a tumor (e.g., cancer) will be sensitive or resistant to a therapy comprising an immune checkpoint inhibitor and/or for monitoring response to a treatment with a therapy comprising an immune checkpoint protein inhibitor.
- a biomarker gene is a tumor suppressor gene.
- Sensitivity or resistance to a therapy with an immune checkpoint protein inhibitor can be determined by analyzing a nucleic acid molecule (DNA, mRNA, cDNA etc.) corresponding to a biomarker gene or the protein encoded by the biomarker gene.
- a nucleic acid molecule DNA, mRNA, cDNA etc.
- Biomarker genes can include any gene whose genotype and/or level of expression in a tissue or cell can be used to predict response to an immune checkpoint inhibitor therapy.
- the detection, and in some cases the level, of one or more biomarker genes of the present disclosure permits the classification of a subject as sensitive or resistant to an immune checkpoint inhibitor therapy.
- a biomarker gene is a tumor suppressor gene.
- a biomarker gene is part of a pathway or otherwise related to one of the biomarker genes disclosed herein. Additional biomarker genes useful in the methods disclosed herein can be identified by those skilled in the art based on the present disclosure.
- the terms “determine,” “determine the genotype of a biomarker gene,” “determine the level of a biomarker gene,” “determine the amount of a biomarker gene,” “determine the biomarker gene level,” and the like are meant to encompass any technique that can be used to detect or measure the genotype, presence, or expression level of one or more biomarker genes. Such techniques can give qualitative or quantitative results. Biomarker gene levels can be determined by detecting the entire biomarker molecule or by detecting fragments or reaction products that are characteristic of the biomarker gene.
- determining, measuring, or taking a measurement refer to a quantitative or qualitative determination of a property of an entity, for example, quantifying the amount or concentration of a molecule or the activity level of a molecule.
- Any known method of detecting or measuring the level of a biomarker can be used to practice the present invention, so long as the method detects the genotype, presence, absence, or expression level of the biomarker gene.
- determining the genotype of a biomarker gene is performed at the nucleic acid level by performing RNA-seq, a reverse transcriptase polymerase chain reaction (RT-PCR) or a hybridization assay with oligonucleotides that are substantially complementary to portions of cDNA molecules of the at least one biomarker gene under conditions suitable for RNA-seq, RT-PCR or hybridization and obtaining expression levels of the at least one biomarker gene.
- RNA-seq a reverse transcriptase polymerase chain reaction
- RT-PCR reverse transcriptase polymerase chain reaction
- hybridization assay with oligonucleotides that are substantially complementary to portions of cDNA molecules of the at least one biomarker gene under conditions suitable for RNA-seq, RT-PCR or hybridization and obtaining expression levels of the at least one biomarker gene.
- cancer refers to the presence of cells possessing characteristics typical of cancer-causing cells, such as uncontrolled proliferation, immortality, metastatic potential, rapid growth and proliferation rate, and certain characteristic morphological features. Cancer cells are often in the form of a tumor, but such cells can exist isolated within an animal, or can be non-tumorigenic, such as a leukemia cell.
- Cancers include, but are not limited to, B cell malignancies, for example, multiple myeloma, , the heavy chain diseases, such as, for example, alpha chain disease, gamma chain disease, and mu chain disease, benign monoclonal gammopathy, and immunocytic amyloidosis, skin cancer, breast cancer, lung cancer, bronchus cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel or appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, cancer of hematological tissues, and the like.
- the heavy chain diseases such as, for example, alpha chain disease, gamma chain
- the cancer is an epithelial cancer such as, but not limited to, bladder cancer, breast cancer, cervical cancer, colon cancer, gynecologic cancers, renal cancer, laryngeal cancer, lung cancer, oral cancer, head and neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, or skin cancer.
- the cancer is breast cancer, prostate cancer, lung cancer, or colon cancer.
- the epithelial cancer is non-small-cell lung cancer, nonpapillary renal cell carcinoma, cervical carcinoma, ovarian carcinoma (for example, serous ovarian carcinoma), or breast carcinoma.
- the amount of a tumor in an individual is the “tumor burden” which can be measured as the number, volume, and/or weight of the tumor.
- Non-limiting exemplary cancers in the embodiments of the present disclosure include skin cancer, lung cancer, pancreatic cancer, breast cancer, colorectal cancer bladder, liver cancer, kidney cancer, leukemia, and lymphoma.
- the cancer is lung cancer.
- the lung cancer is non-small cell lung cancer (NSCLC).
- NSCLC is lung adenocarcinoma.
- the cancer is skin cancer.
- skin cancer is melanoma.
- lung cancer refers to the collection of cancers affecting lung tissue.
- NSCLC Non-small cell lung cancer
- classifying includes associating a sample with a response to an immune checkpoint inhibitor therapy. In certain instances, “classifying” is based on statistical evidence, empirical evidence, or both. In certain embodiments, the methods of classifying utilize a training set of samples having known genotypes. Once established, the training data set can serve as a basis, model, or template against which the features of an unknown sample are compared, to classify the sample.
- control refers to any reference standard suitable to provide a comparison to the expression products in the test sample.
- a control can comprise a reference standard expression product level or genotype score from any suitable source, including but not limited to housekeeping genes, an expression product level range from normal tissue (or other previously analyzed control sample), a previously determined expression product level range within a test sample of a group of patients, or a set of patients with a certain outcome or receiving a certain therapy. It will be understood by those of ordinary skill in the art that such control samples and reference standard expression product levels can be used in combination as controls in the methods of the present invention.
- the biomarker gene expression can be compared to a reference.
- a “reference” can be any value derived by art known methods for establishing a reference.
- expression refers to the biosynthesis of a gene product. The term encompasses the transcription of a gene into RNA. The term also encompasses translation of RNA into one or more polypeptides, and further encompasses all naturally occurring post-transcriptional and post-translational modifications.
- the expressed protein can be within the cytoplasm of a host cell, into the extracellular milieu such as the growth medium of a cell culture or anchored to the cell membrane.
- the term “gene product” as used herein, refers to RNA transcribed from a gene and to one or more proteins, polypeptides of fragments thereof that are the product of translation of the RNA transcribed from the gene, and further encompasses all naturally occurring post- transcriptional and post-translational modifications.
- the expressed protein can be within the cytoplasm of a host cell, into the extracellular milieu such as the growth medium of a cell culture or anchored to the cell membrane.
- the terms “expression level” and “level of expression” as used herein refers to information regarding the relative or absolute level of expression of one or more biomarker genes in a cell or group of cells.
- the level of expression of a biomarker gene can be determined based on the level of RNA, such as mRNA, encoded by the gene. Alternatively, the level of expression can be determined based on the level of a polypeptide or fragment thereof encoded by the biomarker gene.
- Gene expression data can be acquired for an individual cell, or for a group of cells such as a tumor or biopsy sample.
- Gene expression data and gene expression levels can be stored on computer readable media, for example, the computer readable medium used in conjunction with a microarray or chip reading device. Such gene expression data can be manipulated to generate gene expression signatures.
- the expression level of a biomarker gene can be determined using a reagent such as a probe, primer, or antibody and/or a method performed on a biological sample, for example a tumor sample of the subject, for ascertaining or measuring quantitatively, semi-quantitatively or qualitatively the amount of a of a polypeptide or mRNA (or cDNA derived therefrom) corresponding to one or more biomarker genes.
- a reagent such as a probe, primer, or antibody
- a method performed on a biological sample for example a tumor sample of the subject, for ascertaining or measuring quantitatively, semi-quantitatively or qualitatively the amount of a of a polypeptide or mRNA (or cDNA derived therefrom) corresponding to one or more biomarker genes.
- a level of a biomarker gene can be determined by a number of methods including for example immunoassays including for example immunohistochemistry, ELISA, Western blot, immunoprecipitation and the like, where a detection agent such as an antibody for example, a labeled antibody, specifically binds the encoded polypeptide and permits relative or absolute ascertaining of the amount of polypeptide encoded by the biomarker gene, hybridization and PCR protocols where a probe or primer or primer set are used to ascertain the amount of nucleic acid corresponding to the biomarker gene, including for example probe based and amplification based methods including for example microarray analysis, RT-PCR such as quantitative RT-PCR (qRT-PCR), gRT-PCR, serial analysis of gene expression (SAGE), Northern Blot, digital molecular barcoding technology, for example Nanostring Counter Analysis, and TaqMan quantitative PCR assays.
- immunoassays including for example immunohistochemistry, ELISA, Western blot, immunoprecipitation
- mRNA in situ hybridization in formalin-fixed, paraffin-embedded (FFPE) tissue samples or cells which uses probe sets for each mRNA that bind specifically to an amplification system to amplify the hybridization signals; these amplified signals can be visualized using a standard fluorescence microscope or imaging system.
- FFPE paraffin-embedded
- TaqMan probe-based gene expression analysis can also be used for measuring biomarker gene expression levels in tissue samples, including mRNA levels in FFPE samples.
- TaqMan probe-based assays utilize a probe that hybridizes specifically to the mRNA target. This probe contains a quencher dye and a reporter dye (fluorescent molecule) attached to each end, and fluorescence is emitted only when specific hybridization to the mRNA target occurs.
- the exonuclease activity of the polymerase enzyme causes the quencher and the reporter dyes to be detached from the probe, and fluorescence emission can occur. This fluorescence emission is recorded and signals are measured by a detection system; these signal intensities are used to calculate the abundance of a given transcript (gene expression) in a sample.
- nucleic acid can generally refer to a polynucleotide sequence, or fragment thereof.
- a nucleic acid can comprise nucleotides.
- a nucleic acid can be exogenous or endogenous to a cell.
- a nucleic acid can exist in a cell-free environment.
- a nucleic acid can be a gene or fragment thereof.
- a nucleic acid can be DNA.
- a nucleic acid can be RNA.
- mRNA transcripts include but is not limited to pre-mRNA transcript(s), transcript processing intermediates, mature mRNA(s) ready for translation and transcripts of the gene or genes, or nucleic acids derived from the mRNA transcript(s). Transcript processing can include splicing, editing and degradation.
- a nucleic acid derived from an mRNA transcript refers to a nucleic acid for whose synthesis the mRNA transcript or a subsequence thereof has ultimately served as a template.
- a cDNA reverse transcribed from an mRNA, an RNA transcribed from that cDNA, a DNA amplified from the cDNA, an RNA transcribed from the amplified DNA, etc. are all derived from the mRNA transcript and detection of such derived products is indicative of the presence and/or abundance of the original transcript in a sample.
- mRNA derived samples include, but are not limited to, mRNA transcripts of the gene or genes, cDNA reverse transcribed from the mRNA, cRNA transcribed from the cDNA, DNA amplified from the genes, RNA transcribed from amplified DNA, and the like.
- sequencing means determining the identity of at least one nucleotide in the molecule. In certain embodiments, the identity of less than all of the nucleotides in a molecule are determined. In certain embodiments, the identity of a majority or all of the nucleotides in the molecule is determined.
- biological sample refers to any sample obtained from a subject.
- a biological sample can be obtained from a subject prior to or subsequent to a diagnosis, at one or more time points prior to or following treatment or therapy, at one or more time points during which there is no treatment or therapy, or can be collected from a healthy subject.
- the biological sample can be a tissue sample or a fluid sample.
- the biological sample includes a tissue sample, a biopsy sample, a tumor aspirate, a bone marrow aspirate or a blood sample (or a fraction thereof, such as blood or serum).
- the biological sample includes a tumor cell or cancer cell, for example a circulating tumor cell present in a fluid sample, for example, blood or a fraction thereof.
- the biological sample includes a cell free nucleic acid present in a fluid sample, for example, blood or a fraction thereof.
- the biological sample comprises a cell lysate (or lysate fraction) or cell extract; or a solution containing one or more molecules derived from a cell or cellular material (for example a polypeptide or nucleic acid).
- the cell lysate can include proteins, nuclear and/or mitochondrial fractions.
- the cell lysate includes a cytosolic fraction.
- the cell lysate includes a nuclear/mitochondrial fraction and a cytosolic fraction.
- the source of a biological sample can be solid tissue as from a fresh, frozen and/or preserved organ, tissue sample, biopsy, or aspirate; blood or any blood constituents; bodily fluids such as cerebral spinal fluid, amniotic fluid, peritoneal fluid or interstitial fluid; or cells from any time in gestation or development of the subject.
- the biological sample can contain compounds that are not naturally intermixed with the tissue in nature such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics or the like.
- the biological sample can be preserved as a frozen sample or as formaldehyde- or paraformaldehyde-fixed paraffin- embedded (FFPE) tissue preparation.
- FFPE formaldehyde- or paraformaldehyde-fixed paraffin- embedded
- the sample can be embedded in a matrix, for example, an FFPE block or a frozen sample.
- tissue and sample types are amenable for use herein.
- the other tissue and sample types can be fresh frozen tissue, wash fluids, or cell pellets, or the like.
- a biological sample can be a tumor sample, which contains nucleic acid molecules from a tumor or cancer.
- a biological sample that is a tumor sample can be DNA, for example, genomic DNA, or cDNA derived from RNA.
- the tumor nucleic acid sample is purified or isolated (for example, it is removed from its natural state).
- the sample is a tissue (for example, a tumor biopsy), a CTC or cell free nucleic acid.
- a tumor sample is isolated from a human subject.
- the analysis is performed on a tumor biopsy embedded in paraffin wax.
- the sample can be a fresh frozen tissue sample.
- the sample is a bodily fluid obtained from the subject.
- the bodily fluid can be blood or fractions thereof (specifically, serum, plasma), urine, saliva, sputum or cerebrospinal fluid (CSF).
- the sample can contain cellular as well as extracellular sources of nucleic acid.
- the extracellular sources can be cell-free nucleic acids and/or exosomes.
- the methods described herein, including the RT-PCR methods are sensitive, precise and have multi- analyte capability for use with paraffin embedded samples. See, for example, Cronin et al., Am. J Pathol. 164(l):35-42 (2004).
- RNA isolation can be performed using a purification kit, a buffer set and protease from commercial manufacturers according to the manufacturers’ instructions.
- RNA prepared from a tumor can be isolated, for example, by cesium chloride density gradient centrifugation.
- a subject that is likely to respond to a treatment comprising an immune checkpoint inhibitor, such as a PD-1 inhibitor has an increased probability of responding to a treatment comprising the immune checkpoint inhibitor relative to a reference subject or group of subjects.
- a subject that is unlikely to respond to a treatment comprising an immune checkpoint inhibitor such as a PD-1 inhibitor, has a decreased probability of responding to a treatment comprising the immune checkpoint inhibitor relative to a reference subject or group of subjects.
- genomic profiling means sequencing a part or all of the genome of a subject, such as to identify the nucleotide sequence of one or more genes in the subject, such as to identify genomic alterations (for example, mutations) in one or more biomarker genes that would identify the subject as a candidate to receive certain drugs or other therapeutic agents. Genomic profiling can be performed by a method described herein, such as by a next-generation sequencing method, or a massively parallel sequencing method.
- probe refers to any molecule which is capable of selectively binding to a specifically intended target molecule, for example, a nucleotide transcript or protein encoded by or corresponding to a marker. Probes can be either synthesized by one skilled in the art, or derived from appropriate biological preparations. For purposes of detection of the target molecule, probes can be specifically designed to be labeled, as described herein. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.
- the term “genotype” refers to the alleles at one or more specific biomarker genes.
- the genotype of a biomarker gene can be determined by methods that include nucleic acids (RNA, cDNA, and DNA) and proteins, and variants and fragments thereof.
- the term “sensitive” in the context of an immune checkpoint inhibitor therapy means that the immune checkpoint inhibitor therapy is more effective at reducing the tumor relative to a control drug in a subject of the same genotype.
- the term “resistant” in the context of an immune checkpoint inhibitor therapy means that the immune checkpoint inhibitor therapy is less effective at reducing the tumor relative to a control drug in a subject of the same genotype.
- responses to an immune checkpoint inhibitor include sensitivity and resistance compared to the response to a control drug in a subject of the same genotype.
- GSTRs genotype-specific therapeutic responses
- ScoreRTN Relative Tumor Number
- ScoreRGM geometric mean of tumors from the full distribution of tumor sizes
- the resistance and/or sensitivity profiles of one or more biomarker genes for an immune checkpoint inhibitor can be compared to the corresponding resistance and/or sensitivity scores for a standard of care therapy in order to determine whether a subject is likely to benefit from an immune checkpoint inhibitor therapy.
- a PD-1 inhibitor therapy can be compared to standard of care (SoC) therapy for a particular cancer to determine which genotypes are sensitive or resistant relative to the SoC therapy using the described herein. Then, by excluding resistant patients and enrichment for sensitive patients within a prospective patient population, the performance of a PD-1 inhibitor relative to SoC can be improved.
- SoC standard of care
- KEAP1 -deficiency drives selective sensitivity to a combination therapy comprising a PD-1 inhibitor and CTLA-4 inhibitor as compared to a PD-1 inhibitor therapy
- a T -deficiency drives selective resistance to combination therapy comprising a PD-1 inhibitor and CTLA-4 inhibitor as compared to a PD-1 inhibitor therapy.
- the resistance and/or sensitivity profiles of one or more biomarker genes for an immune checkpoint inhibitor can be compared to the corresponding resistance and/or sensitivity scores for a standard of care therapy in order to determine whether a subject is likely to benefit from the immune checkpoint inhibitor therapy. For example, if there are four biomarker genes predictive of resistance to an immune checkpoint inhibitor therapy and two of the four biomarker genes show a lower resistance to an immune checkpoint inhibitor therapy relative to the standard of care therapy, while the other two show a higher resistance relative to the standard of care therapy, only the former two biomarker genes can be used for selecting the subject for an immune checkpoint inhibitor therapy over the standard of care therapy.
- polynucleotide synonymously referred to as “nucleic acid molecule,” “nucleotides” or “nucleic acids,” refers to any polyribonucleotide or polydeoxyribonucleotide, which can be unmodified RNA or DNA or modified RNA or DNA.
- Polynucleotides include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that can be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.
- polynucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA.
- the term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.
- Modified bases include, for example, tritylated bases and unusual bases such as inosine.
- polynucleotide embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells.
- Polynucleotide also embraces relatively short nucleic acid chains, often referred to as oligonucleotides.
- a nucleic acid molecule corresponding to a biomarker gene of the present disclosure can be isolated using standard molecular biology techniques and the sequence information in the database records described herein. Using all or a portion of such nucleic acid sequences, nucleic acid molecules of the present invention can be isolated using standard hybridization and cloning techniques (for example, as described in Sambrook et al., ed., Molecular Cloning: A Laboratory Manual, 2 nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y., 1989).
- a nucleic acid molecule of the present disclosure can be amplified using cDNA, mRNA, or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques.
- peptide can refer to a molecule comprised of amino acids and can be recognized as a protein by those of ordinary skill in the art.
- the conventional one-letter or three-letter code for amino acid residues is used herein.
- peptide can be used interchangeably herein to refer to polymers of amino acids of any length.
- the polymer can be linear or branched, it can comprise modified amino acids, and it can be interrupted by non-amino acids.
- the terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art. [00109] In the case of measuring protein levels to determine biomarker gene expression, any method known in the art is suitable provided it results in adequate specificity and sensitivity. For example, protein levels can be measured by binding to an antibody or an antibody fragment specific for the protein and measuring the amount of antibody -bound protein. Antibodies can be labeled by radioactive, fluorescent or other detectable reagents to facilitate detection. Methods of detection include, without limitation, enzyme-linked immunosorbent assay (ELISA) and immunoblot techniques.
- ELISA enzyme-linked immunosorbent assay
- the methods described herein include determining the genotype of one or more biomarker genes such as ADAR, APC, ARID 1 A, ARJD2, ASXL1, ATM, ATRX, BAP1, BRCA1, BRCA2, CDKN2A, CHD2, CIC, CMTR2, CREBBP, CUL3, DICER1, DLC1, DNMT1, DUSP4, EP 300, FAT1, FBXW7, JAK1, KDM5C, KDM6A, KEAP1, KMT2C, KMT2D, KRAS, LRP1B, MET, MGA, MSH2, MTAP, NCOA6, NF1, NF2, PALB2, PBRM1, PCNA, PTEN, PTPN11, PTPN13, PTPRD, PTPRS, RASA1, RBI, RB1CC1, RBM10, RNF43, SETD2, SMAD2, SMAD4, SMARCA4, SMG1, STAG2, STK11, TET2, TGFBR2,
- the one or more biomarker genes comprise APC, ARID2, ATM, ATRX, BRCA2, CDKN2A, CMTR2, KEAP1, KMT2D, MGA, NF1, PTEN, PTPRD, RBI, RBM10, RNF43, SETD2, SMAD4, STAG2, SIKH, TP53, and TSC1.
- the one or more biomarker genes comprise APC, ARID2, ATM, ATRX, CMTR2, KEAP1, KMT2D, MGA, NF1, PTEN, PTPRD, RBI, RBM10, RNF43, SETD2, SMAD4, STAG2, STK11, and TSC1.
- the one or more biomarker genes comprise BRCA2, CDKN2A, and TP53.
- Keapl -deficiency drives selective sensitivity to combination therapy comprising a PD-1 inhibitor and a CTLA-4 inhibitor in vivo
- 4//77-deficiency drives selective resistance to a combination therapy comprising a PD-1 inhibitor and a CTLA-4 inhibitor in vivo
- /-deficiency drives selective sensitivity to a combination therapy comprising a PD-1 inhibitor and a CTLA-4 inhibitor in vivo
- ATM- deficiency drives selective resistance to combination therapy comprising a PD-1 inhibitor and a CTLA-4 inhibitor in vivo.
- the present disclosure provides a method of predicting response of tumor growth to inhibition by an immune checkpoint inhibitor therapy comprising a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, the method comprising: (a) determining in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting the response of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating KEAP1 mutation, (ii) a decreased copy number of KEAP1, (iii) decreased expression of KEAP1 mRNA or protein, (iv) an inactivating ATM mutation, (v) a decreased copy number of ATM, or
- CTLA-4 cytotoxic T-lymphocyte-associated antigen 4
- the present disclosure provides a method of predicting resistance of tumor growth to inhibition by an immune checkpoint inhibitor therapy comprising a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, the method comprising: (a) detecting in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting resistance of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating ATM mutation, (ii) a decreased copy number of ATM, or (iii) a decreased expression of ATM mRNA or protein.
- CTLA-4 cytotoxic T-lymphocyte-associated antigen 4
- the present disclosure provides a method of predicting sensitivity of tumor growth to inhibition by an immune checkpoint inhibitor therapy comprising a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, the method comprising: (a) detecting in a tumor sample of a subject a genotype of one or more biomarker genes of a biomarker panel comprising; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting sensitivity of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating KEAP1 mutation, (ii) a decreased copy number of KEAP1, or (iii) decreased expression of KEAP1 mRNA or protein.
- CTLA-4 cytotoxic T-lymphocyte-associated antigen 4
- the present disclosure provides a method of treating non-small cell lung cancer (NSCLC), comprising treating a subject with an immune checkpoint inhibitor when a tumor sample obtained from the subject comprises (i) an inactivating KEAP1 mutation, (ii) a decreased copy number of KEAP1, or (iii) decreased expression of KEAP1 mRNA or protein.
- NSCLC non-small cell lung cancer
- the present disclosure provides a method of treating non-small cell lung cancer (NSCLC), comprising treating a subject with a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor when a tumor sample obtained from the subject comprises (i) an inactivating KEAP1 mutation, (ii) a decreased copy number of KEAP1, or (iii) decreased expression of KEAP1 mRNA or protein.
- NSCLC non-small cell lung cancer
- CTLA-4 cytotoxic T-lymphocyte-associated antigen 4
- the tumor sample further comprises, (iv) absence of an inactivating ATM mutation, (v) absence of a decreased copy number of ATM, or (vi) absence of a decreased expression of ATM mRNA or protein.
- the present disclosure provides a method of treating non-small cell lung cancer (NSCLC), comprising treating a subject undergoing a therapy comprising a first immune checkpoint inhibitor and a chemotherapy with a second immune checkpoint inhibitor when a tumor sample obtained from the subject comprises (i) an inactivating KEAP1 mutation, (ii) a decreased copy number of KEAP1, or (iii) decreased expression of KEAP1 mRNA or protein.
- NSCLC non-small cell lung cancer
- the tumor sample further comprises (iv) absence of an inactivating ATM mutation, (v) absence of a decreased copy number of ATM, or (vi) absence of a decreased expression of ATM mRNA or protein.
- the subject is already undergoing a therapy comprising one or more immune checkpoint inhibitors and a chemotherapy.
- the subject is already undergoing an immune checkpoint inhibitor therapy comprising a programmed cell death protein 1 (PD-1) inhibitor and a chemotherapy.
- the methods further comprise selecting a therapy for the subject.
- the therapy comprise a CTLA-4 inhibitor (e.g., a CTLA-4 therapy), for example, an anti-CTLA-4 antibody, e.g., Ipilimumab (Yervoy).
- the PD-1 inhibitor is an anti-PD-1 antibody.
- the PD-1 inhibitor is selected from the group consisting of nivolumab (Opdivo), Pembrolizumab (Keytruda), and Cemiplimab (Libtayo).
- the chemotherapy comprises a taxane, for example, docetaxel, paclitaxel or cabazitaxel.
- the chemotherapy comprises platinum-based agents, for example, cisplatin, carboplatin, oxaliplatin, nedaplatin, and lobaplatin.
- the chemotherapy is selected from Cisplatin, Carboplatin, Paciltaxel (Taxol), Docetaxel (Taxotere), Albuminbound paclitaxel (nab-paclitaxel, Abraxane), Gemcitabine (Gemzar), Vinorelbine (Navelbine), Etoposide (VP- 16), and Pemetrexed (Alimta), or a combination of one or more of these agents.
- Combinations of agents are routinely used to treat early-stage lung cancer. If a combination is used, it can include a platinum-based agent plus one other drug. Sometimes other combinations that do not include these drugs, such as gemcitabine with vinorelbine or paclitaxel, can also be used.
- the present disclosure provides, in part, methods for accurately classifying a subject afflicted with cancer as likely to be sensitive for a therapy comprising an immune checkpoint inhibitor.
- the methods comprise obtaining a tumor sample of the subject and determining a genotype of one or more biomarker genes.
- the biological sample for example, tumor sample
- the biological sample can comprise mRNA molecules or genomic DNA corresponding to the one or more biomarker genes.
- the methods involve obtaining a tumor sample of the subject and contacting the tumor sample with a reagent capable of determining the genotype by detecting, for example, a polypeptide or a nucleic acid that encodes the biomarker gene or fragments thereof.
- the present disclosure provides methods for selecting a subject for treatment with a combination therapy comprising an immune checkpoint inhibitor and a chemotherapy if it is likely that the subject will respond to the combination therapy comprising an immune checkpoint inhibitor and a chemotherapy, wherein the likelihood of response is determined by performing any of the disclosed methods for predicting resistance, sensitivity, or response of tumor growth to inhibition by the therapy on a biological sample obtained from the subject. In certain embodiments, the determination is based on results of an existing biological sample of the subject.
- the present disclosure provides methods for selecting a subject for a therapy comprising a immune checkpoint inhibitor therapy if it is likely that the subject will respond to the immune checkpoint inhibitor therapy, wherein the likelihood of response is determined by performing any of the disclosed methods for predicting resistance, sensitivity, or response of tumor growth to inhibition by the therapy on a biological sample obtained from the subject
- the present disclosure provides methods for selecting a subject undergoing a combination therapy comprising a first immune checkpoint inhibitor and a chemotherapy for a treatment comprising a second immune checkpoint inhibitor if it is likely that the subject will respond to the combination therapy comprising two immune checkpoint inhibitors and a chemotherapy, wherein the likelihood of response is determined by performing any of the disclosed methods for predicting resistance, sensitivity, or response of tumor growth to inhibition by the therapy on a biological sample obtained from the subject. In some embodiments, the determination is based on results of an existing biological sample of the subject.
- the present disclosure provides methods for selecting a subject undergoing treatment with a combination therapy comprising a first immune checkpoint inhibitor and a second immune checkpoint inhibitor if it is likely that the subject will respond to the combination therapy comprising two immune checkpoint inhibitors, wherein the likelihood of response is determined by performing any of the disclosed methods for predicting resistance, sensitivity, or response of tumor growth to inhibition by the therapy on a biological sample obtained from the subject. In some embodiments, the determination is based on results of an existing biological sample of the subject.
- the presently disclosed methods detect mRNA, polypeptide, genomic DNA, or fragments thereof, in a biological sample in vitro as well as in vivo.
- in vitro techniques for detection of mRNA or a fragment thereof include Northern hybridizations and in situ hybridizations.
- in vitro techniques for detection of polypeptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence.
- ELISAs enzyme linked immunosorbent assays
- In vitro techniques for detection of biomarker genomic DNA or a fragment thereof include Southern hybridizations.
- in vivo techniques for detection of one or more polypeptides or fragments thereof include labeled antibodies.
- the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
- the genotype, presence or level of at least one, two, three, four, five, six, seven, eight, nine, ten, fifty, sixty, or more biomarker genes of the invention is determined in the tumor sample.
- the presently disclosed methods employ a statistical algorithm and/or empirical data (for example, the presence or level of one or biomarker genes described herein).
- a single learning statistical classifier system can be used to classify a sample.
- a single learning statistical classifier system typically classifies the sample accurately with a sensitivity, specificity, positive predictive value, negative predictive value, and/or overall accuracy of at least about 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
- learning statistical classifier systems include a machine learning algorithmic technique capable of adapting to complex data sets (for example, panel of markers of interest) and making decisions based upon such data sets.
- a single learning statistical classifier system such as a classification tree (for example, random forest) is used.
- a combination of 2, 3, 4, 5, 6, 7, 8, 9, 10, or more learning statistical classifier systems are used, preferably in tandem.
- Examples of learning statistical classifier systems include, but are not limited to, those using inductive learning (for example, decision/classification trees such as random forests, classification and regression trees (C&RT), boosted trees, etc.), Probably Approximately Correct (PAC) learning, connectionist learning (for example, neural networks (NN), artificial neural networks (ANN), neuro fuzzy networks (NFN), network structures, perceptrons such as multi-layer perceptrons, multi-layer feed-forward networks, applications of neural networks, Bayesian learning in belief networks, etc.), reinforcement learning (for example, passive learning in a known environment such as naive learning, adaptive dynamic learning, and temporal difference learning, passive learning in an unknown environment, active learning in an unknown environment, learning action-value functions, applications of reinforcement learning, and genetic algorithms and evolutionary programming.
- inductive learning for example, decision/classification trees such as random forests, classification and regression trees (C&RT), boosted trees, etc.
- PAC Probably Approximately Correct
- connectionist learning for example, neural networks (NN), artificial neural networks (ANN), neuro fuzzy networks (NFN
- the method of the present invention further comprises sending the cancer classification results to a clinician, for example, an oncologist or hematologist.
- a clinician for example, an oncologist or hematologist.
- determining the genotype of one or more biomarker genes comprises genomic profiling to directly determine the genotype of the one or more biomarker genes.
- genomic profiling comprises contacting the biological sample with reagents, including, probes and/or primers, for sequencing the one or more biomarker genes or a portion thereof.
- probes or primers can be designed to detect a mutation in the one or more biomarker genes.
- the mutation is an inactivating mutation.
- the mutation results in decreased gene expression.
- the methods include directly determining the genotype of one or more biomarker genes by genomic profiling to detect the presence or absence of a genetic alteration characterized by at least one alteration affecting the integrity of a gene encoding one or more biomarkers polypeptide, or the mis-expression of the biomarker (for example, mutations and/or splice variants).
- such genetic alterations can be detected by ascertaining the existence of at least one of a deletion of one or more nucleotides from one or more biomarker genes; an addition of one or more nucleotides to one or more biomarker genes; a substitution of one or more nucleotides of one or more biomarker genes; a chromosomal rearrangement of one or more biomarker genes; an alteration in the level of a mRNA transcript of one or more biomarker genes; aberrant modification of one or more biomarker genes; such as of the methylation pattern of the genomic DNA; the presence of a non-wild type splicing pattern of a messenger RNA transcript of one or more biomarker genes; a non-wild type level of one or more biomarkers polypeptide; allelic loss of one or more biomarker genes, and inappropriate post-translational modification of one or more biomarkers polypeptide.
- PCR polymerase chain reaction
- LCR ligation chain reaction
- This method can include collecting a sample of cells from a subject, isolating nucleic acid from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to one or more biomarker genes of the present disclosure, or fragments thereof, under conditions such that hybridization and amplification of the biomarker gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR can be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.
- Alternative amplification methods include self-sustained sequence replication (Guatelli, J. C. et al. (1990) Proc. Natl. Acad. Sci. USA 87: 1874-1878), transcriptional amplification system (Kwoh, D. Y. et al. (1989) Proc. Natl. Acad. Sci. USA 86: 1173-1177), Q- Beta Replicase (Lizardi, P. M. et al. (1988) Bio-Technology 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.
- mutations in the presently disclosed one or more biomarker genes, or a fragment thereof, from a sample cell can be identified by alterations in restriction enzyme cleavage patterns.
- sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA.
- sequence specific ribozymes can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.
- genetic mutations in the presently disclosed one or more biomarker genes, or a fragment thereof can be identified by hybridizing a nucleic acid to high density arrays containing hundreds or thousands of oligonucleotide probes (Cronin, M. T. et al. (1996) Hum. Mutat. 7:244-255; Kozal, M. J. et al. (1996) Nat. Med. 2:753-759).
- any of a variety of sequencing methods known in the art can be used to directly sequence the presently disclosed one or more biomarker genes, or a fragment thereof, and detect mutations by comparing the sequence of the sample biomarker gene with the corresponding wild-type (control) sequence.
- Non-limiting examples of sequencing reactions include next-generation sequencing to determine the nucleotide sequence of either individual nucleic acid molecules (for example, in single molecule sequencing) or clonally expanded proxies for individual nucleic acid molecules in a highly parallel fashion.
- Next generation sequencing methods are known in the art, and are described, for example, in Metzker, M. (2010) Nature Biotechnology Reviews 11 :31-46.
- Next generation sequencing collectively refers to several DNA/RNA sequencing technologies that vary according to the input material, length of read, and portion of the genome to be sequenced.
- the two major next generation sequencing technologies are short-read sequencing and long-read sequencing.
- Short-read sequencing generally refers to reads that are shorter than 300 bp
- long-read sequencing refers to reads that are longer than 2.5 Kb.
- Short-read sequencing is a relatively inexpensive option (low costs per Gb) that has a high level of accuracy and is used more frequently in clinical practice for the detection of specific mutation hotspots.
- RNA-seq genomic DNA
- RNA-seq messenger or noncoding RNA
- nucleic or ribonucleic material obtained following the use of certain procedures.
- WGS whole genome sequencing
- WES whole-exome sequencing
- targeted gene panels 3 major types being whole genome sequencing (WGS), whole-exome sequencing (WES), and targeted gene panels.
- WGS refers to sequencing the entire genome, including coding and noncoding regions. It allows detection of several types of genetic aberrations, including single nucleotide variants and/or such structural alterations as insertions or deletions (also called indels), copy number variations involving duplications or deletions of long stretches of a chromosomal region, and rearrangements involving gross alterations in chromosomes or large chromosomal regions.
- WES involves sequencing only the coding regions of the genome and is limited in its ability to detect rearrangements between genes with breakpoints that frequently occur in intronic regions.
- RNA-based whole-transcriptome approaches can be another strategy to identify gene rearrangements.
- Targeted gene panels can be performed with either amplicon-based or hybrid-capture enrichment strategies and can range from small, hotspot-only panels focusing on less than fifty genes to larger, more comprehensive panels that include hundreds to greater than a thousand genes with selected intronic tiling coverage.
- the advantages of targeted gene panels include greater analytic sensitivity because of the greater depth of coverage, less complex data analysis and interpretation than would be necessary for WES and WGS, and greater flexibility that allows for tailoring the testing to genomic regions relevant to cancer. Any of the known Next generation sequencing approaches can be practiced for the methods described herein and a skilled person will be able to select the best sequencing strategy to practice the methods described herein.
- determining the genotype of one or more biomarker genes comprises measuring the expression level of one or more biomarker genes.
- the expression level can be measured in a number of ways, including, but not limited to measuring the mRNA encoded by the biomarker genes; measuring the amount of protein encoded by the biomarker genes; and measuring the activity of the protein encoded by the biomarker genes.
- a genotype of a biomarker gene is determined by measuring RNA, cDNA, protein or any combination thereof. When a genotype is determined by measuring RNA, the RNA can be reverse transcribed to produce cDNA (such as by RT-PCR), and the produced cDNA expression level can be detected.
- the expression level of a biomarker gene can be detected by forming a complex between a nucleic acid corresponding to a biomarker gene and a labeled probe or primer.
- the nucleic acid is RNA or cDNA
- the RNA or cDNA can be detected by forming a complex between the RNA or cDNA and a labeled nucleic acid probe or primer.
- the complex between the RNA or cDNA and the labeled nucleic acid probe or primer can be a hybridization complex.
- Another method of determining the genotype of a biomarker gene at the nucleic acid level is the use of an amplification method such as, for example, RT-PCR or quantitative RT- PCR (qRT- PCR).
- Methods for determining the level of mRNA in a sample can involve the process of nucleic acid amplification, for example, by RT-PCR, ligase chain reaction or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. Numerous different PCR or qRT-PCR protocols are known in the art and can be directly applied or adapted for use using the presently described compositions for the detection and/or quantification of expression of biomarker genes in a sample.
- Isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, PCR analyses and probe arrays.
- One method for the detection of mRNA levels involves contacting the isolated mRNA or synthesized cDNA with a nucleic acid molecule (probe) that can hybridize to the mRNA encoded by the gene being detected.
- the nucleic acid probe can be, for example, a cDNA, or a portion thereof, such as an oligonucleotide of at least about 7, about 15, about 30, about 50, about 100, about 250, or about 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to the non-natural cDNA or mRNA.
- biomarker gene expression can be assessed by any of a wide variety of well-known methods for detecting expression of a transcribed molecule or protein.
- Non-limiting examples of such methods include immunological methods for detection of secreted, cell-surface, cytoplasmic, or nuclear proteins, protein purification methods, protein function or activity assays, nucleic acid hybridization methods, nucleic acid reverse transcription methods, and nucleic acid amplification methods.
- activity of a particular biomarker gene is characterized by a measure of gene transcript (for example mRNA), by a measure of the quantity of translated protein, or by a measure of gene product activity.
- Biomarker gene expression can be monitored in a variety of ways, including by detecting mRNA levels, protein levels, or protein activity, any of which can be measured using standard techniques. Detection can involve quantification of the level of gene expression (for example, genomic DNA, cDNA, mRNA, protein, or enzyme activity), or, alternatively, can be a qualitative assessment of the level of gene expression, in particular in comparison with a control level. The type of level being detected will be clear to the skilled person from the context.
- detecting or determining expression levels of a biomarker gene and functionally similar homologs thereof, including a fragment or genetic alteration thereof (for example, in regulatory or promoter regions thereof) comprises detecting or determining RNA levels for the biomarker marker gene.
- one or more cells from the subject to be tested are obtained and RNA is isolated from the cells.
- RNA isolation can be performed using a purification kit, a buffer set and protease from commercial manufacturers according to the manufacturers’ instructions.
- RNA prepared from a tumor can be isolated, for example, by cesium chloride density gradient centrifugation.
- RNA can optionally be enriched, and further be amplified.
- an amplification process such as RT-PCR can be utilized to amplify the mRNA, such that a signal is detectable or detection is enhanced.
- Such an amplification process is beneficial particularly when the biological, tissue, or tumor sample is of a small size or volume.
- Various amplification and detection methods can be used. For example, it is within the scope of the present invention to reverse transcribe mRNA into cDNA followed by polymerase chain reaction (RT-PCR); or, to use a single enzyme for both steps, or reverse transcribe mRNA into cDNA followed by symmetric gap ligase chain reaction (RT-AGLCR).
- RT-PCR polymerase chain reaction
- RT-AGLCR symmetric gap ligase chain reaction
- Northern analysis involves running a preparation of RNA on a denaturing agarose gel, and transferring it to a suitable support, such as activated cellulose, nitrocellulose or glass or nylon membranes. Radiolabeled cDNA or RNA is then hybridized to the preparation, washed, and analyzed by autoradiography.
- RPA RNase protection assays
- PCR- based techniques such as quantitative PCR and differential display PCR.
- Northern blotting involves running a preparation of RNA on a denaturing agarose gel, and transferring it to a suitable support, such as activated cellulose, nitrocellulose or glass or nylon membranes. Radiolabeled cDNA or RNA is then hybridized to the preparation, washed, and analyzed by autoradiography.
- In situ hybridization visualization can also be employed, wherein a radioactively labeled antisense RNA probe is hybridized with a thin section of a biopsy sample, washed, cleaved with RNase and exposed to a sensitive emulsion for autoradiography.
- the samples can be stained with hematoxylin to demonstrate the histological composition of the sample, and dark field imaging with a suitable light filter shows the developed emulsion.
- Non-radioactive labels such as digoxigenin can also be used.
- mRNA expression can be detected on a DNA array, chip or a microarray.
- Labeled nucleic acids of a test sample obtained from a subject can be hybridized to a solid surface comprising biomarker DNA. Positive hybridization signal is obtained with the sample containing biomarker transcripts.
- gene expression can be detected by microarray analysis. Differential gene expression can also be identified or confirmed using a microarray technique. The expression levels of one or more biomarker genes can be measured in either fresh or fixed tissue, using microarray technology. In this method, polynucleotide sequences of interest (including cDNAs and oligonucleotides) are plated, or arrayed, on a microchip substrate.
- the arrayed sequences are then hybridized with specific DNA probes from cells or tissues of interest.
- Fluorescently labeled cDNA probes can be generated through incorporation of fluorescent nucleotides by reverse transcription of RNA extracted from tissues of interest.
- Labeled cDNA probes applied to the chip hybridize with specificity to each spot of DNA on the array.
- the microarray chip is scanned by a device such as, confocal laser microscopy or by another detection method. Quantitation of hybridization of each arrayed element allows for assessment of corresponding mRNA abundance.
- Microarray analysis can be performed by commercially available equipment, following manufacturer's protocols.
- Types of probes that can be used in the methods described herein include cDNA, riboprobes, synthetic oligonucleotides and genomic probes.
- the type of probe used will generally be dictated by the particular situation, such as riboprobes for in situ hybridization, and cDNA for Northern blotting, for example.
- the probe is directed to nucleotide regions unique to the RNA.
- the probes can be as short as is required to differentially recognize marker mRNA transcripts, and can be as short as, for example, about 15 bases; however, probes of at least 17, 18, 19 or 20 or more bases can be used.
- the primers and probes hybridize specifically under stringent conditions to a DNA fragment having the nucleotide sequence corresponding to the marker.
- stringent conditions means hybridization will occur only if there is at least about 95% identity in nucleotide sequences. In another embodiment, hybridization under “stringent conditions” occurs when there is at least 97% identity between the sequences.
- the activity, level or presence of a protein encoded by a biomarker gene can be detected and/or quantified by detecting or quantifying the expressed polypeptide.
- the polypeptide can be detected and quantified by any of a number of means well known to those of skill in the art. Any method known in the art for detecting polypeptides can be used.
- Such methods include, but are not limited to, immunodiffusion, immunoelectrophoresis, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, Western blotting, binder-ligand assays, immunohistochemical techniques, agglutination, complement assays, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, and the like (for example, Basic and Clinical Immunology, Sites and Terr, eds., Appleton and Lange, Norwalk, Conn, pp 217-262, 1991 which is incorporated by reference).
- ELISA and RIA procedures can be conducted such that a desired protein standard is labeled (with a radioisotope such as 125 I or 35 S, or an assayable enzyme, such as horseradish peroxidase or alkaline phosphatase), and, together with the unlabelled sample, brought into contact with the corresponding antibody, whereon a second antibody is used to bind the first, and radioactivity or the immobilized enzyme assayed (competitive assay).
- the protein in the sample is allowed to react with the corresponding immobilized antibody, radioisotope- or enzyme-labeled antibody is allowed to react with the system, and radioactivity or the enzyme assayed (ELISA-sandwich assay).
- Enzymatic and radiolabeling of a protein encoded by a biomarker gene and/or the antibodies can be effected by conventional means. It is possible to immobilize the enzyme itself on a support, but if solid-phase enzyme is required, then this is generally best achieved by binding to antibody and affixing the antibody to a support, models, and systems for which are well-known in the art.
- Immunohistochemistry can be used to detect expression of a protein corresponding to a biomarker gene , for example, in a biopsy sample.
- a suitable antibody is brought into contact with, for example, a thin layer of cells, washed, and then contacted with a second, labeled antibody.
- Labeling can be by fluorescent markers, enzymes, such as peroxidase, avidin, or radiolabelling.
- the assay is scored visually, using microscopy. Any other art-known method can be used to detect a protein corresponding to a biomarker gene.
- a method comprising: (a) determining the genotype of one or more biomarker genes in a biological sample of a subject; and (b) identifying whether the subject is likely to be sensitive to a therapy comprising an immune checkpoint inhibitor based on the genotype.
- a method comprising: (a) determining a genotype of one or more biomarker genes of a biomarker panel comprising ADAR, APC, ARID 1 A, ARID2, ASXL1, ATM, ATRX, BAP1, BRCA1, BRCA2, CDKN2A, CHD2, CIC, CMTR2, CREBBP, CUL3, DICER1, DLC1, DNMT1, DUSP4, EP 300, FAT1, FBXW7, JAK1, KDM5C, KDM6A, KEAP1, KMT2C, KMT2D, KRAS, LRP IB, MET, MG A, MSH2, MTAP, NC0A6, NF1, NF2, PALB2, PBRM1, PCNA, PTEN, PTPN11, PTPN13, PTPRD, PTPRS, RASA1, RBI, RB1CC1, RBM10, RNF43, SETD2, SMAD2, SMAD4, SMARCA4, SMG1, STAG2, SIKH, TET2, TGF
- the biomarker panel comprises APC, ARID2, ATM, ATRX, BRCA2, CDKN2A, CMTR2, KEAP1, KMT2D, MG A, NF1, PTEN, PTPRD, RBI, RBM10, RNF43, SETD2, SMAD4, STAG2, STK11, TP53, and TSC1.
- the biomarker panel comprises APC, CMTR2, KEAP1, KMT2D, MGA, and NF 1.
- the biomarker panel comprises ATM.
- the method of any one of embodiments 1-5 further comprising an initial step of obtaining a biological sample from the subject.
- the biological sample is a tumor sample.
- the genotype comprises a mutation in the one or more biomarker genes.
- the mutation inactivates the one or more biomarker genes. 10.
- determining the genotype comprises genomic profiling.
- determining the genotype comprises measuring gene expression.
- measuring gene expression comprises detection of ribonucleic acids (RNAs) or polypeptides.
- RNAs ribonucleic acids
- cancer selected from the group consisting of skin cancer, lung cancer, pancreatic cancer, breast cancer, and colorectal cancer.
- the lung cancer is non-small cell lung cancer (NSCLC). 0.
- NSCLC non-small cell lung cancer
- the NSCLC is lung adenocarcinoma.
- the method of embodiment 17, wherein the cancer is skin cancer.
- the method of embodiment 21, wherein the skin cancer is melanoma.
- the immune checkpoint inhibitor comprises an antibody or an antigen-binding fragment thereof.
- the immune checkpoint inhibitor is an anti-PD- 1 antibody
- the immune checkpoint inhibitor is selected from the group consisting of nivolumab (Opdivo), Pembrolizumab (Keytruda), and Cemiplimab (Libtayo).
- the immune checkpoint inhibitor is an anti-PD- L1 antibody, optionally wherein the immune checkpoint inhibitor is selected from the group consisting of Atezolizumab (Tecentriq), avelumab (Bevencio), and durvalumab (Imfinzi).
- a method of predicting resistance of tumor growth to inhibition by a therapy comprising an immune checkpoint inhibitor comprising: (a) detecting in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting resistance of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating BRCA2, CDKN2A, or TP53 mutation, (ii) a decreased copy number of BRCA2, CDKN2A, or TP53, or (iii) a decreased expression of BRCA2, CDKN2A, or TP53 mRNA or protein.
- a method of predicting sensitivity of tumor growth to inhibition by a therapy comprising an immune checkpoint inhibitor comprising: (a) detecting in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting sensitivity of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating APC, ARID2, ATM, ATRX, CMTR2, KEAP1, KMT2D, MGA, NF1, PTEN, PTPRD, RBI, RBM10, RNF43, SETD2, SMAD4, STAG2, STK11, or TSC1 mutation, (ii) a decreased copy number of APC, ARID 2, ATM, ATRX, CMTR2, KEAP1, KMT2D, MGA, NF1, PTEN, PTPRD, RBI, RBM10, RNF43, SETD2, SMAD4, STAG2, SIKH
- a method of predicting response of tumor growth to inhibition by a therapy comprising an immune checkpoint inhibitor comprising: (a) determining in a tumor sample of a subject a genotype of one or more biomarker genes of a biomarker panel comprising APC, ARID2, ATM, ATRX, BRCA2, CDKN2A, CMTR2, KEAP1, KMT2D, MGA, NF1, PTEN, PTPRD, RBI, RBM10, RNF43, SETD2, SMAD4, STAG2, SIKH, TP53, and TSCF, (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting the response of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating APC, ARID2, ATM, ATRX, CMTR2, KEAP1, KMT2D, MGA, NF1, PTEN, PTPRD, RBI, RBM10, RNF43, SETD2, SMAD
- a method of determining effectiveness of an immune checkpoint inhibitor in reducing tumor size comprising: (a) treating a first inert tumor with a control therapy; (b) treating a second inert tumor with an immune checkpoint inhibitor, wherein the first and second inert tumors comprise identical genotypes; (c) treating a first mutant tumor with the control therapy; (d) treating a second mutant tumor with the immune checkpoint inhibitor, wherein the first and second mutant tumors comprise identical genotypes; (e) comparing sizes of the first and second inert tumors after the therapy; (f) comparing sizes of the first and second mutant tumors after completion of the therapy, and (g) identifying the mutant tumor genotype as sensitive to the immune checkpoint inhibitor if the change in tumor size between the first and second inert tumors after the therapy is less than the change in tumor size between the first and second mutant tumors after the therapy.
- a method of determining effectiveness of an immune checkpoint inhibitor in reducing tumor size comprising: (a) treating a first inert tumor with a control therapy; (b) treating a second inert tumor with an immune checkpoint inhibitor, wherein the first and second inert tumors comprise identical genotypes; (c) treating a first mutant tumor with the control therapy; (d) treating a second mutant tumor with the immune checkpoint inhibitor, wherein the first and second mutant tumors comprise identical genotypes; (e) comparing sizes of the first and second inert tumors after the therapy; (f) comparing sizes of the first and second mutant tumors after completion of the therapy, and (g) identifying the mutant tumor genotype as resistant to the immune checkpoint inhibitor if the change in tumor size between the first and second inert tumors after the therapy is greater than the change in tumor size between the first and second mutant tumors after the therapy.
- a method of predicting resistance of tumor growth to inhibition by a therapy comprising an immune checkpoint inhibitor comprising: (a) detecting in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting resistance of tumor cell growth to inhibition by the therapy comprising the immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating ATM mutation, (ii) a decreased copy number of ATM, or (iii) a decreased expression of ATM mRNA or protein.
- a method of predicting sensitivity of tumor growth to inhibition by a therapy comprising an immune checkpoint inhibitor comprising: (a) detecting in a tumor sample of a subject a genotype of one or more biomarker genes of a biomarker panel comprising; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting sensitivity of tumor cell growth to inhibition by the therapy comprising the immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating APC, CMTR2, KEAP1, KMT2D, MGA, or NF1 mutation, (ii) a decreased copy number oiAPC, CMTR2, KEAP1, KMT2D, MGA, or NF 1, or (iii) decreased expression of APC, CMTR2, KEAP1, KMT2D, MGA, or NF1 mRNA or protein.
- a method of predicting response of tumor growth to inhibition by a therapy comprising an immune checkpoint inhibitor comprising: (a) determining in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting the response of tumor cell growth to inhibition by the therapy comprising the immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating APC, CMTR2, KEAP1, KMT2D, MGA, or NF1 mutation, (ii) a decreased copy number of APC, CMTR2, KEAP1, KMT2D, MGA, or NF1, (iii) decreased expression of APC, CMTR2, KEAP1, KMT2D, MGA, or NF 1 mRNA or protein; (iv) an inactivating ATM mutation, (v) a decreased copy number of ATM, or (vi) a decreased expression of ATM mRNA or protein.
- a method of enriching a prospective patient population for subjects likely to respond to an immune checkpoint inhibitor therapy comprising performing the method of any one of any one of embodiments 39 to 47 on two or more individual subjects within the prospective patient population.
- tumor sample corresponds to a cancer selected from the group consisting of skin cancer, lung cancer, pancreatic cancer, breast cancer, and colorectal cancer.
- NSCLC non-small cell lung cancer
- the immune checkpoint inhibitor is an anti-PD- 1 antibody, optionally wherein the immune checkpoint inhibitor is selected from the group consisting of nivolumab (Opdivo), Pembrolizumab (Keytruda), and Cemiplimab (Libtayo).
- the immune checkpoint inhibitor is an anti-PD- L1 antibody, optionally wherein the immune checkpoint inhibitor is selected from the group consisting of Atezolizumab (Tecentriq), avelumab (Bevencio), and durvalumab (Imfinzi).
- the chemotherapy comprises docetaxel, paclitaxel or cabazitaxel.
- the chemotherapy comprises platinum-based chemotherapy.
- a method of treating non-small cell lung cancer comprising treating a subject with a therapy comprising an immune checkpoint inhibitor when a tumor sample obtained from the subject comprises the genotype of any one of any one of embodiments 39-64.
- a method of predicting resistance of tumor growth to inhibition by an immune checkpoint inhibitor therapy comprising a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor comprising: (a) detecting in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting resistance of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating ATM mutation, (ii) a decreased copy number of ATM, or (iii) a decreased expression of ATM mRNA or protein.
- CTLA-4 cytotoxic T-lymphocyte-associated antigen 4
- a method of predicting sensitivity of tumor growth to inhibition by an immune checkpoint inhibitor therapy comprising a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor comprising: (a) detecting in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting sensitivity of tumor cell growth to inhibition by the therapy comprising an immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating KEAP1 mutation, (ii) a decreased copy number of KEAP1, or (iii) decreased expression of KEAP1 mRNA or protein.
- CTLA-4 cytotoxic T-lymphocyte-associated antigen 4
- a method of predicting response of tumor growth to inhibition by an immune checkpoint inhibitor therapy comprising a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor comprising: (a) determining in a tumor sample of a subject a genotype of one or more biomarker genes; (b) analyzing the genotype of the one or more biomarker genes in the tumor sample; and (c) predicting the response of tumor cell growth to inhibition by the therapy comprising the immune checkpoint inhibitor, if the tumor sample comprises (i) an inactivating KEAP1 mutation, (ii) a decreased copy number of KEAP1, (iii) decreased expression of KEAP1 mRNA or protein, (iv) an inactivating ATM mutation, (v) a decreased copy number o ATM, or (vi) a decreased expression of ATM mRNA or protein.
- CTLA-4 cytotoxic T-lymphocyte-associated antigen 4
- CTLA-4 inhibitor is anti-CTLA-4 antibody, optionally wherein the CTLA-4 inhibitor is Ipilimumab (Yervoy).
- a method of enriching a prospective patient population for subjects likely to respond to an immune checkpoint inhibitor therapy comprising a cytotoxic T-lymphocyte- associated antigen 4 (CTLA-4) inhibitor comprising performing the method of embodiment 68 on two or more individual subjects within the prospective patient population.
- CTLA-4 cytotoxic T-lymphocyte- associated antigen 4
- the tumor sample corresponds to a cancer selected from the group consisting of skin cancer, lung cancer, pancreatic cancer, breast cancer, and colorectal cancer.
- lung cancer is non-small cell lung cancer (NSCLC).
- NSCLC non-small cell lung cancer
- the PD-1 inhibitor is anti-PD-1 antibody, optionally wherein the PD-1 inhibitor is selected from the group consisting of nivolumab (Opdivo), Pembrolizumab (Keytruda), and Cemiplimab (Libtayo).
- a method of treating non-small cell lung cancer comprising treating a subject with an immune checkpoint inhibitor when a tumor sample obtained from the subject comprises (i) an inactivating KEAP1 mutation, (ii) a decreased copy number of KKAP1, or (iii) decreased expression of KEAP1 mRNA or protein.
- CTLA-4 inhibitor is an anti-CTLA-4 antibody, optionally wherein the CTLA-4 inhibitor is Ipilimumab (Yervoy).
- tumor sample further comprises, (iv) absence of an inactivating ATM mutation, (v) absence of a decreased copy number of ATM, or (vi) absence of a decreased expression of ATM mRNA or protein.
- the immune checkpoint inhibitor is an anti-PD- 1 antibody, optionally wherein the immune checkpoint inhibitor is selected from the group consisting of nivolumab (Opdivo), Pembrolizumab (Keytruda), and Cemiplimab (Libtayo).
- a method of treating non-small cell lung cancer comprising treating a subject undergoing a therapy comprising a first immune checkpoint inhibitor and a chemotherapy with a second immune checkpoint inhibitor when a tumor sample obtained from the subject comprises (i) an inactivating KEAP1 mutation, (ii) a decreased copy number of KEAP1, or (iii) decreased expression of KEAP1 mRNA or protein.
- tumor sample further comprises (iv) absence of an inactivating ATM mutation, (v) absence of a decreased copy number of ATM, or (vi) absence of a decreased expression of ATM mRNA or protein.
- the first immune checkpoint inhibitor is an anti- PD-1 antibody, optionally wherein the first immune checkpoint inhibitor is selected from the group consisting of nivolumab (Opdivo), Pembrolizumab (Keytruda), and Cemiplimab (Libtayo).
- CTLA-4 cytotoxic T-lymphocyte-associated antigen 4
- the CTLA-4 inhibitor is an anti-CTLA-4 antibody, optionally wherein the CTLA-4 inhibitor is Ipilimumab (Yervoy).
- This example describes the identification of tumor suppressor genes that are biomarkers of response to immune checkpoint inhibitor therapies through a method that integrates CRISPR/Cas9-based somatic genome engineering and molecular barcoding into established Cre/Lox-based genetically engineered mouse models of oncogenic Kras-driven lung cancer.
- This example shows, inter alia, that Keapl -deficiency drives selective sensitivity to a combination therapy comprising a PD-1 inhibitor and a CTLA-4 inhibitor in vivo, while Atm- deficiency drives selective resistance to a combination therapy comprising a PD-1 inhibitor and a CTLA-4 inhibitor in vivo.
- Lentiviral vectors carrying Cre as well as an sgRNA targeting each of 22 known and putative lung adenocarcinoma tumor suppressors Ape, Arid2, Atm, Atrx, Brca2, Cdkn2a, Cmtr2, Keapl, Kmt2d, Lkbl, Mga, Nfl, p53, Pten, Ptprd, Rbl, RbmlO, Rnf43, Setd2, Smad4, Stag2, Tscl, Fbxw7, Kdm6a, Kras WT, Msh2, Nf2, Palb2, Pena, Shp2, Jakl, Adar, Pbrml, Dnmtl, and Trexl, were generated.
- Vectors were also generated carrying inert guides: sgRosa26-l, sgRosa26-2, sgRosa26-3, sgNT-1, sgNT-2, and sgNT-3. All possible 20-bp sgRNAs (using an NGG PAM) targeting each tumor suppressor gene of interest were identified and scored for predicted on-target cutting efficiency using an available sgRNA design/scoring algorithm (Doench et al., Nat Biotechnol 34, 184-191 (2016). https://doi.org/10.1038/nbt.3437).
- sgRNAs predicted to be the most likely to produce null alleles was selected; preference was given to sgRNAs that were previously validated in vivo (Rogers et al., Nat Methods. 2017 Jul;14(7):737-742. doi: 10.1038/nmeth.4297; Rogers et al., Nat Genet. 2018 Apr;50(4):483-486. doi: 10.1038/s41588- 018-0083-2; Winters et al. Nat Commun. 2017 Dec 12;8(l):2053. doi: 10.1038/s41467-017- 01519-y.
- PMID 29233960
- PMCID PMC5727199
- QnA-j6-sgRNA Cre vectors containing each sgRNA were generated as previously described (Rogers et al.. Nat Methods.
- the Lenii-sgRHA Cre vectors with a 46bp multi-component barcode cassette that would be unique to each tumor were diversified by virtue of stable integration of the lentiviral vector into the initial transduced cell.
- This 46 bp DNA barcode cassette was comprised of a known 6-nucleotide ID specific to the vector backbone (vectorlD), a 10-nucleotide ID specific to each individual sgRNA (sgID), and a 30-nucleotide random barcode containing 20 degenerate bases (random BC).
- the 46 bp barcode cassette for each sgRNA was flanked by universal Illumina® TruSeq adapter sequences and synthesized as single stranded DNA oligos. Forward and reverse primers complimentary to the universal TruSeq sequences and containing 5’ tails with restriction enzyme sites (Asci and Notl) were used in a PCR reaction to generate and amplify double stranded barcode cassettes for cloning. Each Lenti-sgRNA-Cre vector and its matching insert barcode PCR product was digested with Asci and Noth
- Electroporatio- transformed cells were immediately recovered by adding into 5 ml pre-warmed SOC media. From this 5 ml cells in SOC medium, 10 pl were further diluted with LB ampicillin broth and a final dilution of 1 :200K was plated on LB ampicillin plate for incubation at 37°C. The remaining cells in SOC medium were mixed gently and thoroughly before being inoculated into 100 ml LB/Ampicillin broth, shaking at 220 rpm at 37°C overnight. The next day, colony number on LB/Ampicillin plate were counted to estimate the complexity of each library while 100 ml bacteria culture were pelleted for plasmid purification.
- barcoded en -sgRRA Cre vectors targeting the 22 tumor suppressor genes (Ape, Arid2, Atm, Atrx, Brca2, Cdkn2a, Cmtr2, Keapl, Kmt2d, Lkbl, Mga, Nfl, p53, Pten, Ptprd, Rbl, RbmlO, Rnf43, Setd2, Smad4, Stag2, and Tscl) and those containing the inert, negative control sgRNAs (sgRosa26-l, sgRosa26-2, sgRosa26-3, sgNT-1, sgNT-2, and sgRT-3) were combined such that the viruses would be at equal ratios in relation to their estimated titers. This pool was then diluted with 1 x DPBS to reach
- Lung tumors in Kras LSL ' G12D/+ , Hl 1 LSL - Cas9 (KC) mice were initiated via intratracheal delivery of 180,000 functional units (FU) of a lentivirus pool containing barcoded Lenti-U6-sgRNA/PGK-Cre vectors targeting either 22 genes (Ape, Arid2, Atm, Atrx, Brca2, Cdkn2a, Cmtr2, Keapl, Kmt2d, Lkbl, Mga, Nfl, p53, Pten, Ptprd, Rbl, RbmlO, Rnf43, Setd2, Smad4, Stag2, and Tscl) plus 6 negative control sgRNAs (three targeting the Rosa26 gene, which are actively cutting but functionally inert, and 3 non-cutting sgRNAs with no expected genomic target [sgNon-Targeting: sgNT]).
- FU functional units
- mice 12 weeks post tumor initiation, mice were treated with the following:
- DNA barcode cassettes comprised of known 46 bp sequences were flanked by universal Illumina® TruSeq adapter sequences and synthesized as single stranded DNA oligos. Forward and reverse primers complimentary to the universal TruSeq sequences and containing 5’ tails with restriction enzyme sites (Xbal and BstBl) were used in a PCR reaction to generate and amplify double stranded barcode cassettes for cloning. A lentivector pRCMERP-CMV- MCS-EFl-TagR-Puro and each of the barcode insert PCR products were digested by Xbal and BstBl restriction enzymes.
- Each digested barcode insert was cloned into linearized vector by T4 DNA ligase and transformed into OmniMax chemical competent cells (Invitrogen). Colonies from each transformation plate were screened by PCR and sequencing. One positive clone from each barcode containing construct was cultured for plasmid DNA extraction.
- Virus was packaged from each of the barcoded pRCMERP constructs in 6-well plates using pPack packaging mix and LipoD293 reagent. Virus containing medium were collected at 48 hours post transfection and filtered with Nalgene 0.2 pm PES filter before being frozen down in aliquots at -80°C. Small aliquot of frozen viruses were thawed and added into HEK293 cells in 12-well plate for measuring titer by FACS analysis 72 hours after transduction.
- virus containing medium was added to HEK293 cells at MOI 0.1 in 10cm plates. After overnight incubation, cells were recovered in fresh EMEM complete medium for 48 hours before splitting into a new plate containing lug/ml puro in complete EMEM medium for puro selection.
- barcode-containing HEK293 cells were recovered in fresh EMEM complete medium without puro for another 3 days before being further expanded in 10cm plates. Each established cell line was quality controlled by PCR amplification of the barcode region from genomic DNA to confirm integration of correct barcode sequences.
- DNA barcode cassettes comprised of 46 bp barcode cassettes and flanked by universal Illumina® TruSeq adapter sequences as well as additional buffer sequences to extend their total length to >400bp were generated either by direct synthesis of the double-stranded DNA fragments (GeneWiz, IDT) or synthesis of single-stranded DNA oligos (GeneWiz, IDT) with overlapping complementary regions that were extended and amplified via PCR to create double-stranded DNA products that were then purified. Aliquots of these stock double-stranded DNA fragments were diluted to the desired copy numbers using DNase-free ultra-pure H2O and stored at -20°C. [00193] Isolation o f Genomic DNA from Mouse Lungs
- PCR products were purified using SPRI beads.
- concentration of purified PCR products from individual mice was determined by TapeStation (Agilent Technologies). Sets of 20-60 samples were pooled at equal ratios. Samples were sequenced on an Illumina® NextSeq and (Cellecta).
- Paired-end sequencing reads were demultiplexed via dual indexes and adapters sequences were trimmed. Paired-end alignments were constructed between mate-paired reads and library-specific databases of the expected oligonucleotide and tumor barcode insert sequences. These alignments were stringently filtered from downstream analysis if they failed to meet any of a number of quality criteria, including:
- the resulting clusters are each considered to represent an error-corrected sequence equal to that of the sequence that founded the cluster and read count equal to the sum of the read counts of the dereplicated reads that are members of the cluster.
- the read counts of each unique barcode were converted to tumor cell sizes by dividing the number of error-corrected reads of an oligonucleotide that had been spiked into the sample prior to tissue homogenization and lysis at a fixed, known concentration.
- shrinkage of inert tumors was estimated by finding the S that matches the median number of tumors in larger than a cutoff L in such paired groups after the vehicle- treated tumor sizes are multiplied by S (S ⁇ 1 when the inhibitor works to shrink tumors). Subsequently, for each non-inert tumor genotype, the ratio of the number of tumors with this genotype larger than L in the control mice to the number of tumors larger than L*S in the treated mice was computed. The resulting ratio was divided by the same ratio computed for the inert tumors, and the log2(») of this ratio of ratios was determined. This metric, RTNscore is expected to be > 0 for resistant genotypes and ⁇ 0 for sensitive genotypes.
- FIG. 2 shows the multiplexed analysis of immunotherapy responses in the autothchonous mouse model of lung adenocarcinoma performed in Example 1.
- FIG. 2A shows an experimental schematic depicting the composition of the pool of barcoded Lenti-sgRNA/Cre vectors (Lenti-D2G ⁇ ‘P° 0 Cre) used in Example 1.
- FIG. 2B shows mouse genotype, analysis time points, and readouts.
- FIG. 2C shows effects of each tumor genotype on growth. Tumors at the indicated percentiles of the tumor size distribution for each barcoded Lenti-sgRNA/Cre vector are shown. 95% confidence intervals are indicated.
- Panel d. shows the treatment groups in this study. Antibodies, dosing, and number of mice are indicated.
- FIG. 3 shows that Keapl -deficiency drives selective sensitivity to a combination therapy comprising a PD-1 inhibitor and a CTLA-4 inhibitor in vivo.
- FIG. 3 A and FIG. 3B show genotype specific responses to PD-1 inhibitor-treated relative to control -treated mice (FIG. 3 A) and PD-1 inhibitor- and CTLA-4 inhibitor-treated mice relative to control treated mice (FIG. 3B).
- Significant sensitive effects are shown for Ape in FIG. 3 A, and Ape, Cmtr2, Keapl, Kmt2d, and Nfl in FIG. 3B.
- Significant resistant effects are shown for Atm in FIG. 3B.
- FIG. 3C shows genotype specific responses to PD-1 inhibitor-treated and CTLA-4 inhibitor- treated mice relative to PD-1 inhibitor-treated mice. Significant sensitive effects are shown for Keapl and significant resistant effects are shown for Atm in FIG. 3C.
- FIG. 3D shows a volcano plot of the magnitude of differential sensitivity to a PD-1 inhibitor treatment and a CTLA-4 inhibitor treatment relative to PD-1 inhibitor treatment alone.
- FIG. 3 further shows Atm- deficiency drives selective resistance to a combination therapy comprising a PD-1 inhibitor and a CTLA-4 inhibitor in vivo.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente divulgation concerne des méthodes d'identification de sujets qui sont susceptibles de répondre à des thérapies par inhibiteur de point de contrôle immunitaire. Par exemple, dans certains modes de réalisation, les méthodes consistent à : (a) déterminer un génotype d'un ou de plusieurs gènes biomarqueurs dans un échantillon biologique d'un sujet atteint d'une tumeur (par exemple, le cancer); (b)déterminer un génotype de chacun du ou des gènes biomarqueurs dans l'échantillon biologique; et (c) classer un sujet comme sensible ou résistant à une thérapie comprenant un inhibiteur de point de contrôle immunitaire sur la base du génotype de chacun du ou des gènes biomarqueurs dans l'échantillon biologique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263302941P | 2022-01-25 | 2022-01-25 | |
US63/302,941 | 2022-01-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023147306A2 true WO2023147306A2 (fr) | 2023-08-03 |
WO2023147306A3 WO2023147306A3 (fr) | 2023-09-21 |
Family
ID=87472503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/061169 WO2023147306A2 (fr) | 2022-01-25 | 2023-01-24 | Biomarqueurs pour prédire la réactivité à une thérapie par inhibiteur de point de contrôle immunitaire |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023147306A2 (fr) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017025962A1 (fr) * | 2015-08-10 | 2017-02-16 | Tel Hashomer Medical Research, Infrastructure And Services Ltd | Prédiction de la réponse à une immunothérapie basée sur des biomarqueurs tumoraux |
AU2018240195A1 (en) * | 2017-03-20 | 2019-10-17 | Caris Mpi, Inc. | Genomic stability profiling |
-
2023
- 2023-01-24 WO PCT/US2023/061169 patent/WO2023147306A2/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023147306A3 (fr) | 2023-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sanchez-Carbayo et al. | Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome | |
Tejpar et al. | Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery | |
Tahira et al. | Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer | |
US9670549B2 (en) | Gene expression signatures of neoplasm responsiveness to therapy | |
US7890267B2 (en) | Prognostic and diagnostic method for cancer therapy | |
EP1824997B1 (fr) | Alterations genetiques utiles pour predire la response de neoplasies malignes a des traitements medicaux bases sur le taxane | |
US20130042333A1 (en) | Markers for cancer prognosis and therapy and methods of use | |
CA3056896A1 (fr) | Profilage de stabilite genomique | |
US20170283885A1 (en) | Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors | |
US20140256564A1 (en) | Methods of using hur-associated biomarkers to facilitate the diagnosis of, monitoring the disease status of, and the progression of treatment of breast cancers | |
KR20220130108A (ko) | 범-암 백금 반응 예측기 | |
US20090098538A1 (en) | Prognostic and diagnostic method for disease therapy | |
US20230178245A1 (en) | Immunotherapy Response Signature | |
US20200270702A1 (en) | Classification of diffuse large b-cell lymphoma | |
JP2005333987A (ja) | 悪性血液疾患の予後 | |
Liao et al. | Gene expression and splicing alterations analyzed by high throughput RNA sequencing of chronic lymphocytic leukemia specimens | |
JP2008523822A (ja) | 急性骨髄性白血病患者を評価するための方法 | |
US20110236396A1 (en) | Methods and compositions for diagnosing and treating a colorectal adenocarcinoma | |
WO2023109875A1 (fr) | Biomarqueurs pour le traitement du cancer colorectal | |
WO2023284736A1 (fr) | Biomarqueurs pour le traitement du cancer colorectal | |
WO2017083513A1 (fr) | Procédés de classification de myélomes multiples | |
Lei et al. | Noncoding SNP at rs1663689 represses ADGRG6 via interchromosomal interaction and reduces lung cancer progression | |
WO2023147306A2 (fr) | Biomarqueurs pour prédire la réactivité à une thérapie par inhibiteur de point de contrôle immunitaire | |
US20230304102A1 (en) | Biomarkers for predicting responsiveness to shp2 inhibitor therapy | |
US20230383360A1 (en) | Biomarkers for predicting responsiveness to mek inhibitor monotherapy and combination therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23747787 Country of ref document: EP Kind code of ref document: A2 |